ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421688] -Menopausal Women With E R+/H ER2– Breast Cancer in the 
Neoadjuvant Setting  
Protocol Number:  ARV -471- BC-201 
Study Intervention Number:  ARV -471 (PF -07850327)  
Study Intervention Name:  [CONTACT_340768]:  2 
US IND Number:  [ADDRESS_421689] Number:  2021-005081-17  
Brief Title:  A Phase 2 neoadjuvant study of ARV -471 and anastrozole  
Sponsor Name:  [CONTACT_340769], Inc 
(Arvinas) 
Legal Registered Address:  [ADDRESS_421690] [ZIP_CODE]  
Date of Original Protocol:  27 May 2022  
Date of Global Amendment #1 : 09 Jan 2023 
 
This document is the confidential and proprietary information of Arvinas Estrogen Receptor, Inc. (Arvinas). 
By [CONTACT_52212], you agree to keep it confidential and to use and disclose it solely for the 
purpose of assessing whether your organization will participate in and/or the performance of the proposed sponsored s
tudy. Any permitted disclosures will be made only on a confidential “need to know” basis within 
your organization or to your independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by [CONTACT_340726]. Any supplemental information (eg, amendments) that may be added to this document is also confidential and proprietary to Arvinas and must be kept in confidence in the same manner as the contents of this docum ent. 
Any person who receives this document without due authorization from Arvinas is requested to return it to 
Arvinas or promptly destroy it. All other rights reserved. References to Arvinas in this protocol may apply to 
partners to which Arvinas has tran sferred obligations, eg, a contract research organization.  
 

ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421691] OF FIGURES  ............................................................................................................. 10  
DOCUMENT HISTORY  .................................................................................................... 11  
1. PROTOCOL SUMMARY  ............................................................................................... 14  
1.1. Synopsis  .................................................................................................................... 14  
1.2. Schema  ..................................................................................................................... 21  
1.3. Schedule of Activities  ............................................................................................... 22  
2. INTRODUCTION ........................................................................................................... 27  
2.1. Study Rationale  ......................................................................................................... 27  
2.2. Background ............................................................................................................... 28  
2.2.1. Clinical Overview  ......................................................................................... 29  
[IP_ADDRESS]. ARV -471 ..................................................................................... 29  
[IP_ADDRESS]. Anastrozole  .................................................................................. 34  
2.3. Benefit/Risk Assessment  ........................................................................................... 35  
2.3.1. Risk Assessment  ........................................................................................... 35  
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS  ......................................................... 36  
4. STUDY DESIGN  ............................................................................................................ 37  
4.1. Overall Design .......................................................................................................... 37  
4.2. Scientific Rationale for Study Design  ........................................................................ 37  
4.2.1. Rationale for Selection of Patient Population ................................................. 37  
4.2.2. Rationale for Selection of Control Arm  ......................................................... 37  
4.2.3. Rationale for Duration of Treatment  .............................................................. 38  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 3 
 4.2.4. Collection of Retained Research Samples ...................................................... 38  
4.3. Justification for Dose  ................................................................................................ 38  
4.3.1. ARV -471 ...................................................................................................... 38  
4.3.2. Anastr ozole ................................................................................................... 39  
4.4. Safety Review Committee  ......................................................................................... 39  
4.5. Start and End of Study Definition  .............................................................................. 39  
5. STUDY POPULATION  .................................................................................................. 39  
5.1. Inclusion Criteria  ...................................................................................................... 40  
5.2. Exclusion Criteria  ..................................................................................................... 41  
5.3. Lifestyle Considerations  ............................................................................................ 43  
5.4. Screen Failures  .......................................................................................................... 43  
5.4.1. Re -testing During Screening  ......................................................................... 43  
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  ................................ 43  
6.1. Study Intervention(s) Administered  ........................................................................... 44  
6.1.1. Administration  .............................................................................................. 44  
[IP_ADDRESS]. Arm A  .......................................................................................... 44  
[IP_ADDRESS]. Arm B  .......................................................................................... [ADDRESS_421692] Complaints  .......................................................................... 46  
6.3. Assignment to Study Intervention  ............................................................................. 46  
6.4. Study Intervention Compliance  ................................................................................. 46  
6.5. Dose Modification and Treatment Discontinuation  .................................................... 47  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 4 
 6.5.1. ARV -471 ...................................................................................................... 47  
6.5.2. Anastrozole  ................................................................................................... 49  
6.6. Continued Access to Study Intervention After the End of the Study  .......................... 49  
6.7. Treatment of Overdose  .............................................................................................. 49  
6.8. Prior and Concomitant Therapy  ................................................................................. 50  
6.8.1. Prohibited Therapy  ........................................................................................ 50  
[IP_ADDRESS]. ARV -471 ..................................................................................... 50  
[IP_ADDRESS]. Anastrozole  .................................................................................. 51  
[IP_ADDRESS]. Other Prohibited and/or Limited us e of 
Anti-tumor/Anti- Cancer or Experimental Drugs, or Procedures  ............ 51  
6.8.2. Other Restrictions and Precautions  ................................................................ 51  
6.8.3. Supportive Care  ............................................................................................ 51  
6.9. Surgical Resection ..................................................................................................... 51  
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ........................................................................ 52  
7.1. Criteria for Stoppi[INVESTIGATOR_178144]  .................................................................................. 52  
7.2. Discontinuation of Study Intervention  ....................................................................... 52  
7.3. Participant Discontinuation/Withdrawal From the Study  ........................................... [ADDRESS_421693] to Follow -Up ..................................................................................................... 54  
8. STUDY ASSESSMENTS AND PROCEDURES  ............................................................ 55  
8.1. Efficacy Assessments  ................................................................................................ 56  
8.1.1. Disease Response Assessment  ....................................................................... 56  
[IP_ADDRESS]. Imaging and Clinical Assessment  ................................................. 56  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 5 
 [IP_ADDRESS]. Radiographic Imaging Assessment  ............................................... 56  
[IP_ADDRESS]. Physical Exam: Caliper -based Measurements  ............................... 56  
[IP_ADDRESS]. Local Pathological Assessment of Tissue from Surgical 
Resection  ............................................................................................. 56  
8.2. Safety Assessments  ................................................................................................... 57  
8.2.1. Physical Examinations  .................................................................................. 57  
8.2.2. Vital Signs  .................................................................................................... 57  
8.2.3. Electrocardiograms  ....................................................................................... 58  
8.2.4. Clinical Safety Laboratory Assessments  ........................................................ 58  
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting  ...................... 59  
8.3.1. Time Period and Frequency for Collecting AE and SAE Information  ............ 59  
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety  ................................................... 60  
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF  ........................ 60  
8.3.2. Method of Detecting AEs and SAEs .............................................................. 61  
8.3.3. Follow -Up of AEs and SAEs ......................................................................... 61  
8.3.4. Regulatory Reporting Requirements for SAEs  .............................................. 61  
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, 
and Occupational Exposure  ................................................................................ 62  
[IP_ADDRESS]. Exposure During Pregnancy ......................................................... 62  
[IP_ADDRESS]. Exposure During Breastfeeding .................................................... 63  
[IP_ADDRESS]. Occupational Exposure  ................................................................. 64  
8.3.6. Lack of Efficacy ............................................................................................ 64  
8.3.7. Medication Errors  ......................................................................................... 64  
8.4. Pharmacokinetics  ...................................................................................................... 65  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 6 
 8.4.1. Collection of Samples  ................................................................................... 65  
[IP_ADDRESS]. Determination of Drug Concentration  ........................................... 65  
[IP_ADDRESS]. Determination of Pharmacokinetic of Individual Participants  ....... 65  
8.5. Genetics  .................................................................................................................... 65  
8.5.1. Specified Genetics  ........................................................................................ 65  
8.6. Biomarkers ................................................................................................................ 66  
8.6.1. Mandator y Tumor Biopsies  ........................................................................... 66  
9. STATISTICAL CONSIDERATIONS  ............................................................................. 66  
9.1. Statistical Hypotheses  ............................................................................................... 66  
9.1.1. Multiplicity Adjustment ................................................................................ 66  
9.1.2. Estimands  ..................................................................................................... 67  
[IP_ADDRESS]. Primary Estimands  ....................................................................... 67  
[IP_ADDRESS]. Secondary Estimands  ................................................................... 67  
9.2. Analysis Sets  ............................................................................................................. 67  
9.3. Statistical Analyses  ................................................................................................... 68  
9.3.1. General Considerations  ................................................................................. 68  
9.3.2. Primary Safety/Efficacy Analyses  ................................................................. 69  
9.3.3. Secondary Endpoint(s)/Estimands Analysis ................................................... 69  
9.3.4. Tertiary/Exploratory Endpoint(s)  .................................................................. 69  
9.3.5. Subgroup Analyses  ....................................................................................... 69  
9.3.6. Other Safety Analyses  ................................................................................... 70  
9.4. Sample Size Determination  ....................................................................................... 70  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ...................................................................................................... 73  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 7 
 10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  .................... 73  
10.1.1. Regulatory and Ethical Considerations  ........................................................ 73  
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP  ........................................................................... 73  
10.1.2. Financial Disclosur e .................................................................................... 74  
10.1.3. Informed Consent Process  ........................................................................... 74  
10.1.4. Data Protection  ........................................................................................... 75  
10.1.5. Committees Structure  .................................................................................. 75  
10.1.6. Dissemination of Clinical Study Data  .......................................................... 75  
10.1.7. Data Quality Assurance  ............................................................................... 76  
10.1.8. Source Documents  ...................................................................................... 77  
10.1.9. Study and Site Start and Closure  ................................................................. 77  
10.1.10. Publication Policy  ..................................................................................... 78  
10.1.11. Sponsor’s Qualified Medical Personnel  ..................................................... 78  
10.2. Appendix 2: Clinical Laboratory Assessments  ......................................................... 79  
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting  ........................................................................ 81  
10.3.1. Definition of AE  ......................................................................................... 81  
10.3.2. Definition of an SAE  ................................................................................... 82  
10.3.3. Recording/Reporting and Follow -Up of AEs and/or SAEs During the 
Active Collection Period  .................................................................................... 83  
10.3.4. Reporting of SAEs  ...................................................................................... 86  
10.4. Appendix 4: Contraceptive and Barrier Guidance  .................................................... 88  
10.5. Appendix 5: Genetics  .............................................................................................. 89  
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments  ............. 90  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 8 
 10.7. Appendix 7: ECG Findings of Potential Clinical Concern ....................................... 92  
10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI  ............ 94  
10.9. Appendix 9: Alternative Measures During Public Emergencies  ............................... 96  
10.9.1. Eligibility  .................................................................................................... 96  
10.9.2. Telehealth Visits  ......................................................................................... 96  
10.9.3. Study Intervention  ....................................................................................... 96  
10.9.4. Adverse Events and Serious Adverse Events  ............................................... 97  
10.9.5. Treatment for COVID While on Study  ........................................................ 97  
10.9.6. Guidance for COVID vaccine administration .............................................. 97  
[IP_ADDRESS]. For Participants Who Have Not Initiated Study Treatment .......... 97  
[IP_ADDRESS]. For Participants Already on Study Treatment and Beyond 
Cycle 1  ................................................................................................. 97  
10.10. Appendix 10: Eastern Cooperative Oncology Group Performance Status  .............. 98  
10.11. Appendix 11: Radiological Imaging Assessment: modified RECIST 1.[ADDRESS_421694] 1.1 Disease Assessment  ............................................. 100  
[IP_ADDRESS]. Measurable Lesions at Baseline  .............................................. 100  
[IP_ADDRESS]. Nontarget Lesions at Baseline ................................................. 100  
[IP_ADDRESS]. Normal Sites of Disease .......................................................... 100  
[IP_ADDRESS]. Recording Modified RECIST 1.1 Tumor Assessments  ........... 101  
10.11.3. Disease Response Status at Each Imaging Assessment  ............................ 102  
[IP_ADDRESS]. Target Disease Response Status  .............................................. 103  
[IP_ADDRESS]. Nontarget Disease Response Status  ........................................ 103  
[IP_ADDRESS]. New Lesions  ........................................................................... 104  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 9 
 [IP_ADDRESS]. Overall Response at Each Imaging Assessment  ...................... 104  
10.12. Appendix 12: Abbreviations ................................................................................ 106  
10.13. Appendix 13: Protocol Amendment History  ........................................................ 110  
10.14. Appendix 14: Signature [CONTACT_68615]  ............................................................................. 111  
10.14.1. Sponsor Approval Page  ........................................................................... 111  
10.14.2. Investigator Acknowledgment  ................................................................. 112  
11. REFERENCES  ............................................................................................................ 113  
 
  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421695] Description  ..................................................................... 44  
Table 5  Study Treatment  .................................................................................... 44  
Table 6  Dose Reduction – Guidance for Adverse Events Related to ARV -
471 (Except QTcF Prolongation)  ........................................................... 49  
Table 7  Confidence Intervals for Mean Percentage of Baseline Value in Ki -
67 After Two Weeks  ............................................................................. 71  
Table 8  Confidence Intervals for the Ratio Between the Mean Percentage of 
Baseline Values for Ki -67 Observed from ARV -471 and 
Anastrozole Arms (Ki -67 Evaluable Participants N=120)  ...................... [ADDRESS_421696] OF FIGURES  
Figure 1  ARV -471 Significantly Inhibits Tumor Growth and Reduces ER 
Levels in the MCF7 Xenograft Model  ................................................... 30  
 
  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 11 
 DOCUMENT HISTORY  
Document  Date of Issue  
Original protocol  27 May 2022  
 Amendment to Original Protocol  14 Dec 2022 
Global Amendment  #1 09 Jan 2023 
 
Protocol Amendment Summary of Key Changes Table  
Global Amendment #1 (09- JAN-2023) 
Overall Rationale for the Amendment: To align the protocol with the most current version 
of the Investigator’s Brochure, , add 
mRECIST, and further clarify some operational aspects of the study.  
Substantial Amendment: No 
Section # and Name  [CONTACT_340770]  
1.1 Synopsis and 
throughout Surgical resection accepted C6D18  
± 14 days instead of  C6D18 ± 10 
days To allow the sites more flexibility in 
scheduling of surgery. 
1.1 Synopsis  Inclusion clarified to participants 
for whom neoadjuvant endocrine 
monotherapy is deemed appropriate  Study population f urther clarified  
 
 
1.1 Synopsis  Addition to exclusion criteria #[ADDRESS_421697] be done in triplicate  and on a 
vendor ma chine  Clarification of the  process for 
substitution of screening for C1D1 ECGs 
at baseline.  
[IP_ADDRESS].3  Nonclinical 
Pharmacokinetics and 
Drug-Drug 
Interactions  Removed language that indicat ed PPIs 
are allowed and added details  to 
Section [IP_ADDRESS]  indicating that PPIs are 
not recommended.  To align  section with the most current 
version of the Investigator’s Brochure 
(version 4.0).  
[IP_ADDRESS]  Anastrozole  Addition of s uggestion for bone 
mineral density testing  Added language regarding bone mineral 
density from the anastrozole SmPC  
 
 
4.3.1  ARV -471 Additional information provided 
regarding  suggested ARV -471 dose To align  section with  more current  data 
to support dose selection.  

ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 12 
 Section # and Name  [CONTACT_340770]  
5.1 Inclusion Criteria  Inclusion clarified to participants for 
whom neoadjuvant endocrine 
monotherapy is deemed appropriate   Study population further clarified  
 
 
5.2 Exclusion Criteria   Addition  to exclusion criteria #[ADDRESS_421698] ase deficiency or glucose-
galactose malabsorption .  Included further detail on population of 
patients that should be excluded from 
study  
  
6 Study 
Intervention (s) and 
Concomitant Therapy  Bulk bottle supply language removed 
from Table 4  Bulk bottles will no longer be used in 
this study.  
6.1.1  Administration  Study drug may be continue d beyond 
C6D18 + 14 days if surgical resection 
is delayed for non-study related reasons 
and after discussion with medical 
monitor.  To allow  patients to continue dosing 
study drug  beyond C6D18 + 14 days 
after discussion with medical monitor.  
6.5.1  ARV -471 Clarification in footnotes in Table 6 
that only one dose re -escalation is 
permitted.  Clarification  that only one dose re -
escalation of ARV -471 will be allowed.  
6.8 Prior and 
Concomitant Therapy Additional detail added regarding 
herbal supplements and concomitant 
medications . Herbal supplements are 
not recommended. Other concomitant 
medications may be considered on a 
case-by-case basis .  Given potential for interactions with 
herbal supplements , language added 
indicating they are not recommended on 
study. 
[IP_ADDRESS]  ARV -471 Details added regarding co -
administration of PPIs and H2 
blockers . The concomitant use of PPIs 
with ARV-471 is not recommended . 
H2 blockers (eg, cimetidine, 
famotidine) or local antacids (eg, 
aluminum hydroxide, calcium 
carbonate, bismuth subsalicylate) may 
be used.  To align concomitant  medications 
section with the most curr ent version of 
the Investigator’s Brochure (version 4.0).  
[IP_ADDRESS]  Other 
Prohibited and/or 
Limited use of Anti -
tumor/Anti-Cancer or 
Experimental Drugs, 
or Procedures  Clarification added  for therapi[INVESTIGATOR_340703] -cancer effects  Clarification  that the on-study  
prohibition of anti-cancer therapi[INVESTIGATOR_340704] . 
6.8.2  Other 
Restrictions and 
Precautions  Clarification added  for participation in 
any other interventional or 
non-interventional studies  To allow for pr ospective  evaluation of 
participation in any other investigational 
study  by [CONTACT_131989].  
[IP_ADDRESS]  Radiographic 
Imaging Assessment  Added MRI as preferred imaging 
modality  RECIST 1.[ADDRESS_421699] lesions in the neoadjuvant 
setting . 
[IP_ADDRESS]  Radiographic 
Imaging Assessment  Modifications made to include 
modified RECIST 1.1 (see also 
Appendix 11)  Clarification  that mRECIST  will be used 
to define response.  

ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 13 
 Section # and Name  [CONTACT_340770]  
8.2.3  
Electrocardiogram s Clarification that i f screening ECG is 
obtained on a vendor machine within 
96 hours of C1D1 in triplicates, there is 
no need to repeat the pre -dose ECG 
testing on C1D1.  
 
Details added regarding co llection of 
ECGs. All triplicate ECG tracings will 
be sent electronically to a central ECG 
laboratory for manual interval 
measurements. All ECG’s must be 
reviewed by [CONTACT_340727]. If vendor ECG machine 
readings return an abnormal ECG 
finding, the investigator may use 
their site machine to repeat the 
assessment.  Clarification  on the process for 
collecting ECGs and interactions with 
central ECG vendor.  
8.3.[ADDRESS_421700] administration of 
study intervention.  
[IP_ADDRESS] Recording 
Nonserious AEs and 
SAEs on the CRF  Clarification that t he recording of non -
serious AEs and SAEs will continue 
until [ADDRESS_421701] administration 
of study intervention . Clarification as to when recording of 
non-serious AEs and SAEs will stop . 
9.3.1 General 
Considerations  Clarification that CIs will be two -sided.  Stats clarification.  
9.3.3 Secondary 
Endpoint(s)/Estimands 
Analysis  Clarification that r adiographic response 
will be evaluated per mRECIST. To align evaluation with addition of 
Appendix 11.  
10.11  Appendix 11: 
Radiological Imaging 
Assessment: modified 
Requirements and 
RECIST 1.[ADDRESS_421702] 
for this trial.  
 
 
 
 
 
 
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 14 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Name [CONTACT_790]/Company: Arvinas Estrogen Receptor, Inc. (Arvinas)  
Name [CONTACT_791](s): ARV -471 and anastrozole  
Title of Study: An open -label, randomized, non -comparative Phase [ADDRESS_421703]- menopausal women with ER+ /HER2 – breast cancer in the 
neoadjuvant setting  
Study Centers:  Multicenter, global [US, [LOCATION_013], Georgia, and Spain]  
Phase of Development: Phase 2  
Objectives, Endpoints and Estimands:  
Objective   Endpoints   
Primary   
Evaluate the effects of ARV -471 and 
anastrozole , respectively,  on Ki -67 
expression in tumors after 2 weeks of 
treatment  Percent change in Ki -67 expression between baseline 
and C1D15 tumor biopsies  
Estimand: See Section  [IP_ADDRESS] . 
Secondary   
Evaluate the safety and tolerability of 
ARV -471 and anastrozole, respectively  Incidence of all adverse events , serious adverse events , 
and adverse events  leading to study drug 
discontinuation   
Evaluate the clinical and pathological 
response of ARV -471 and anastrozole, 
respectively  Pathologic stage, pathologic complete response ( pCR) 
rate, and modified Pre -operative Endocrine Prognostic 
Index ( mPEPI ) score at the time of surgical resection 
(C6D18 ± 14 days); rates of breast conserving surgery 
(BCS ); radiographic response of the primary tumor 
based on breast imaging during cycle 6; caliper -based 
response on C6D1   
Exploratory   
Evaluate the effects of ARV -471 and 
anastrozole , respectively , on CCCA after 2 
weeks of treatment   CCCA (Ki -67 ≤2.7%) rates at C1D15  
Evaluate ER degradation by [CONTACT_340728] -471  Percent change in ER protein levels between baseline 
and C1D15  
Evaluate the effects of ARV -471 and 
anastrozole , respectively,  on Ki -67, and 
ER degradation by [CONTACT_340728] -471 in tumors at 
the time of surgical resection   Changes in ER and Ki -67 expression between baseline 
and Cycle 6 surgical tumor samples; Rates of CCCA in 
the Cycle 6 surgical samples  
Explore additional biomarkers that may be 
associated with the effects of ARV -471 in 
tumor tissue   Additional biomarkers may include, but are not limited 
to, PgR  expression,  
 
Correlate exposure of ARV -471 with ER 
reduction   Correlate population PK model -derived PK parameters 
(AUC, C min, C max) with ER reduction or other response 
parameters  
 

ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 15 
 Rationale/Overall Study Design:  
Clinical trials evaluating pre -operative endocrine therapy in hormone receptor positive 
(HR+ ) human epi[INVESTIGATOR_3506] 2 negative  (HER2 –) breast cancer allow 
for rapid assessment of novel therapeutic approaches (Guerrero -Zotano 2017; Denduluri 
2018). Several trials evaluating pre -operative endocrine therapy have focused on biologic 
endpoints in tumor samples. In particular, Ki -67 has been used as a biomarker to assess the 
activity of ER -targeting agents, and Ki -67 results in the  neoadjuvant setting may correlate 
with outcomes in the adjuvant or metastatic setting (Guerrero -Zotano 2017).  
 
This trial is a Phase [ADDRESS_421704]- menopausal women with ER+ /HER2 – localized breast cancer. AR V-471 is an orally 
bioavailable PROteolysis  TArgeting Chimera ( PROTAC®) small molecule that induces 
active degradation of the ER via recruitment of the cereblon E3 ligase. Anastrozole is an aromatase inhibitor ( AI) that is commonly used (and considered SOC) in the neoadjuvant 
treatment of post -menopausal women with HR+ breast cancer.  
 
This trial will provide the first opportunity to evaluate the pharmacodynamic effects, 
safety, and activity of ARV -471 in a treatment -naïve setting. It will also allow evalua tion 
of the PD activity (mainly via Ki- 67) of ARV -471 or anastrozole in the treatment -naïve 
setting. These results will help inform future definitive studies in early and late -stage 
ER+/HER2 – breast cancer.  
 Overall Design:  
This is a Phase 2, open- label, randomized, non- comparative proof of concept  study of 
ARV -471 or anastrozole in participants with ER+ /HER2 – breast cancer amenable to 
definitive surgical resection. The main goal of this study is to evaluate the biological activity of ARV -471 and anastrozole , respectively .  
 Participants will be randomized in a 2:1 manner to receive treatment on one of two 
treatment arms for approximately 5.5 months:  
• Arm A: ARV- 471 200 mg PO, daily and continuously until the day before surgic al 
resection (no later than C6D18 + 14 days)  
• Arm B: anastrozole 1 mg PO, daily and continuously until the day before surgical 
resection (no later than C6D18 + 14 days)  
Stratification will occur based  on the following features of the participant’s breast cancer:  
• Size of primary breast tumor (T -stage): ≤2 cm, >2 to <5 cm, or ≥5 cm.  
• Ki-67 score (assessed locally): <20% or ≥20% 
Participants will have a screening biopsy, an on- treatment biopsy on C1D15 (+ 5 days), and 
surgical resection approximately 5.5 months  after starting treatment (C6D18  ± 14 days). 
Participants will return for follow up 30 days (+7 days) after definitive surgical resection. 
After surgery, participants will receive standard of care radiation and systemic therapy 
(chemotherapy, endocrine the rapy, etc.) in accordance with local practice guidelines per 
the treating physician’s discretion. No participant should take study drug dispensed for the 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 16 
 trial after surgical resection, and no study drug should be dispensed after surgical 
resection.  
 
A Safety Review Committee  will review all data from participants enrolled in this study.  
Number of Participants (Planned):  
Approximately 150 participants are expected to be enrolled (~100 participants in Arm A 
and 50 participants in Arm B). It is estimated that this sample size will provide 
approximately 120 (80 in Arm A and 40 in Arm B) participants with evaluable paired 
biopsies (screening and C1D15 biopsies).  
Diagnosis and Main Criteria for Eligibility:  
Participants must meet all of the inclusion and exclusion criteria specified in Section  5 of 
the protocol.  
 
Participants for whom neoadjuvant endocrine monotherapy is deemed appropriate are 
eligible for inclusion in this study only if all the following key inclusion criteria are met:  
 
Type of participant and target disease characteristics:  
• Post-menopausal females ≥[ADDRESS_421705] one of the following: prior 
bilateral oophorectomy, age ≥60, or age <[ADDRESS_421706] 
12 months (i n the absence of chemotherapy, tamoxifen, toremifene, ovarian 
suppression, or any additional medical intervention that may have induced amenorrhea) and follicle stimulating hormone /estradiol in the postmenopausal 
range  
• Histologically or cytologically conf irmed ER+ and HER2 – breast cancer (per local 
assessment). ER and HER2 status must be documented:  
o ER+ disease, with ER staining of ≥10% of tumor cell nuclei by [CONTACT_340729] /CAP Guidelines (Allison 2020) .  
o HER2 – disease by [CONTACT_340730] n per ASCO/CAP 
guidelines  
o Ki-67 score ≥5%, analyzed locally  
• Clinical T1c -T4c, N0 -N2, M0 breast cancer amenable to definitive surgical 
resection, without bilateral breast ductal carcinoma in situ or invasive breast cancer  
• The primary tumor must be at leas t 1.5 cm by [CONTACT_9661]  
• ECOG performance status of 0 or 1  
• Willingness to undergo a screening biopsy, an on- treatment biopsy and surgical 
resection  
Laboratory Findings:  
• Adequate bone marrow function defined as follows (with no transfusion of blood products or use of hematopoietic growth factors in the 28 days prior to enrollment):  
• Absolute neutrophil count of ≥1500/mm
3 or ≥1.5 × 109/L  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 17 
 • Platelets of ≥100,000/mm3 or ≥100  ×109/L  
• Hemoglobin ≥9 g/dL  
• aPTT  ≤1.25  × ULN and INR  ≤1.25  
• Unless the participant is receiving anticoagulation, then aPTT and INR should be 
within the therapeutic range of the intended use.  
• Adequate renal function defined as serum creatinine of ≤1.5 × ULN or an estimated 
creatinine clearance of ≥60 mL/min by [CONTACT_340731]  
• Adequate liver function defined as:  
• Total serum bilirubin of ≤1.5 × ULN unless the participant has documented Gilbert 
syndrome. Participants with Gilbert syndrome must have total serum bilirubin 
≤3 × ULN.  
• AST and ALT of ≤2.5  × ULN  
Participan ts will not be eligible for this study if any of the following key exclusion criteria 
are met:  
Medical conditions:  
• Any other active malignancy within 3 years prior to enrollment, except for 
adequately treated basal cell or squamous cell skin cancer, or cervical carcinoma in 
situ  
• Any of the following in the previous 6 months:  
o Myocardial infarction  
o Severe unstable angina  
o Coronary/peripheral artery by[CONTACT_9292]  
o Symptomatic congestive heart failure ([LOCATION_001] Heart Association class III or IV)  
o Cerebrovascular accident  
o Transient ischemic attack  
o Symptomatic pulmonary embolism or other clinically significant epi[INVESTIGATOR_340705] 
• Any of the following in the previous 6 months:  
o Congenital long QT syndrome  
o Torsade de Pointes  
o Sustained ventricular tachyarrhythmia and ventricular fibrillation  
o Left anterior hemiblock (bifascicular block)  
o Ongoing cardiac dysrhythmias of NCI CTCAE ≥Grade 2  
o Atrial fibrillation of any grade (≥Grade 2 in the case of asymptomatic lone 
atrial fibrillation)  
• QTcF >470 msec  
• Active, uncontrolled bacterial, fungal or viral infection, including HBV, HCV, and HIV or AIDS -related illness  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 18 
 • Active inflammatory gastrointestinal disease, chronic diarrhea, known uncontrolled 
diverticular disease, or previous gastric resection or lap band surgery  
• Cirrhosis meeting criteria for Child Pugh B and C  
Prior/concomitant therapy:  
• Prior treatment for breast cancer including systemic therapy ( eg, chemotherapy, 
hormonal therapy), radiation, surgery, or any investigational agents  
• Any live vaccines within [ADDRESS_421707] dose of study drug.  
• Taking the following agents within 14 days of C1D1 unless otherwise specified:  
o Sensitive P -gp substrates or P -gp substrates with narrow therapeutic indices  
o Strong CYP3A4 inhibitors or inducers  
o Any medications with known QT risk, and/or are associated with a risk of 
Torsades de Pointes, within 7 days of C1D1  
• Major surgery (as defined by [CONTACT_737]) within four weeks of first dose of study drug  
Allergy and other drug reactions:  
• History of allergy or reaction to any of the drug components for ARV -[ADDRESS_421708] ase deficiency or glucose -galactose malabsorption.  
Other criteria:  
• Inability to take oral medication without crushing, dissolving, or chewing tablets  
Study Intervention, Dosage and Mode of Administration : 
ARV -471 will be dosed at 200 mg administered orally once a day, continuously 
throughout each 28- day cycle until the day before surgery (no later than 
C6D18 + 14 days).  
 
Anastrozole will be dosed at 1 mg administered orally once a day, continuously throughout 
each 28 -day cycle until the day before surgery (no later than C6D18 + 1 4 days) . 
Duration of Treatment:  
Planned Study Duration:  Approximately 18 months (time from first participant enrolled 
until all participants have completed the study).   
Planned Treatment Duration:  Participants will continue treatment with ARV -471 or 
anastrozole for approximately 5.5 months prior to undergoing surgical resection (no later than C6D18 +  14 days), and in the absence of disease progression that may jeopardize the 
opportunity for definitive surgery, unacceptable toxicity, participant withdrawal or 
Investigator’s decision or other criteria as defined in Section 7 of the protocol.   
Statistical Methods:  
Sample S ize Determination   
This is a Phase 2 proof of concept  study designed to generate data informing future studies 
about ARV -471. There are no plans for formal comparisons between ARV -471 and 
anastrozole. Descriptive statistics (including point estimates and two -sided confidence 
intervals ) will be provided for a ll parameters of interest. Approximately 150 participants 
will be randomized to the two treatment arms in a 2:1 ratio (100 participants to the ARV -471 arm and 50 participants to the anastrozole arm). These numbers were chosen to 
provide meaningful informat ion about the primary endpoint, ie, changes (on -treatment 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 19 
 C1D15 vs baseline) in Ki -67 expression levels after approximately 2 weeks of treatment 
with ARV-471 or anastrozole. Assume that 80% of the randomized participants will 
provide valid Ki -67 measuremen ts from both their baseline and C1D15 biopsies . Also 
assume that Ki -67 will reduce to approximately 20 to 40% of their corresponding baseline 
values after 2  weeks of treatment. The width of the 80% CIs of the mean percentage Ki-67 
with ARV- 471 will not exc eed 14% and the width of the 95% CIs will not exceed 21.6%. 
The planned sample size will provide estimates for the treatment effect in terms of the 
reduction of Ki -67 with reasonable precision.  
  
Primary Safety/Efficacy Analyses   
Statistical analyses for the primary and secondary endpoints are summarized here. Additional analyses are described in Section 9 and in the SAP.
 
  
Analyses for PD endpoints including the primary endpoint:   
Ki-67 expression will be assessed by [CONTACT_340732] a central 
laboratory.  
  
Analysis of Ki -67 reduction will be based on a Ki -67 evaluable population.  The 
log-transformed percentage change in Ki -67 after approximately 2 weeks of treatment, ie, 
the ratio between the Ki -67 measurements obtained from C1D15 visit and baseline, will be 
modelled using a GLM, with both stratification factors ( ie, baseline Ki -67 score and the 
tumor size) and treatment as covariates. Treatment effects for each arm will be 
summarized using the LSM and their two-sided confidence intervals  on the log scale. In 
addition, for easier interpretation of the data, the treatment effects will be back transformed and expressed as the geometric means and their confidence intervals  on the original 
percentage scale by [CONTACT_2939].  Similar modeling will be applied to ER data.
 
 
CCCA at week 2 is defined as Ki67 score ≤2.7%. An estimate of the difference in CCCA 
rates and corresponding 80% as well as 95% CIs will be calculated using Cochran 
Mantel -Haenszel methodology. Odds ratios between the treatment will be provided along 
with corresponding CIs.  
 
Analyses for clinical and pathologic response endpoints:   
pCR is defined as  no invasive cancer in the breast and sampled axillary lymph nodes 
following completion of neoadjuvant systemic therapy.  
 
mPEPI [INVESTIGATOR_340706] a numerical score following neoadjuvant 
endocrine therapy, including Ki67 expression in the surgical specimen, pathologic tumor 
size and lymph node status.  The proportion of participants achieving mPEPI [INVESTIGATOR_32005] 0 after 
treatment will be evaluated.  
  
To support the secondary objective of evaluating clinical and pathologic response, binary or categorical endpoint such as pathologic stage, pCR, and participants with mPEPI [INVESTIGATOR_32005] 
0 at the time of surgical resection (C6D18 ± 14 days), rates of breast conserving surgery , 
radiographic response per mRECI ST in the primary tumor during cycle [ADDRESS_421709] CI 
using Wilson  method; for caliper -based response on C6D1, best percentage change from 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421710] grade per NCI CTCAE v5.0 criteria. The extent of exposure including number of doses, duration of 
treatment, and dose modifications will be summarized by [CONTACT_2939]. A summary of 
deaths with reasons will be provided for all treated participants.   
 
  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421711] -menopausal women with ER+ /HER2 – localized breast cancer.  
Clinical trials evaluating pre -operative endocrine therapy in ER+ /HER2 – breast cancer allow 
for rapid assessment of novel therapeutic approaches (Guerrero -Zotano 2017; 
Denduluri 2018) . Pre-operative therapy can potentially downstage and improve suitability of 
breast conservation. Endocrine therapy is the therapeutic mainstay for ER + breast cancer and 
targets ER activity and/or estrogen synthesis; however, many patients experience disease 
relapse or treatment resistance. Up to 20% of patients diagnosed with early- stage breast 
cancer relapse in the first 10 years, often with distant metastases  (Johnston 2020).  
Several trials evaluating pre- operative endocrine therapy have focused on biologic activity 
endpoints in tumor samples (Ellis 2008 ; Smith 2005; Ellis 2011 ). Ki-[ADDRESS_421712]. Several large trials 
demonstrate results in the neoadjuvant setting correlate to relapse free survival after 
definitive surgical resection (Smith 2020, Ellis 2008 ) and outcomes in the adjuvant or 
metastatic setting (Guerrero -Zotano 2017 ). For example, the improved Ki -[ADDRESS_421713] and P024 trial 
(Ellis 2008 , Smith 2005 ) parallels the improved disease -free survival seen  with AIs in the 
adjuvant setting (The BIG 1 -98 Collaborative Group 2005, Howell 2005) . Furthermore, the 
similarity in Ki- 67 suppression between nsAIs and sAIs in the neoadjuvant setting (Ellis 
2011)  parallels the similar disease -free survival  with these agents in the adjuvant setting 
(Goss 2013, Smith 2017).  
ARV -471 is an orally bioavailable PROteolysis  TArgeting Chimera ( PROTAC®) small 
molecule that induces active degradation of the ER via recruitment of the cereblon E3 ligase. In the ongoing FIH study, ARV -[ADDRESS_421714] ER 
degradation, and preliminary  evidence of  clinical activity in participants with 
advanced/metastatic breast cancer who received prior CDK 4/6 inhibitors (Section  [IP_ADDRESS].5 ; 
Hamilton  2022) . Based on these data in combination with pre -surgical trials demonstrating 
SERDs have biological activity and a tolerable safety profile in early breast cancer 
(Lerebours 2016, Kuter 2012, Ma 2020, Hurvitz 2022a ), ARV -[ADDRESS_421715]-menopausal 
women with HR+ HER2 – breast cancer both in clinical practice and in clinical trials 
(Ma 2020, Hurvitz 2020 , Hurvitz 2022a ). Anastrozole has also been approved for the 
treatment of HR+ breast cancer in the adjuvant and advanced/metastatic setting, and these results will help inform future definitive s tudies of ARV -471 in early- and late- stage 
ER+/HER2 – breast cancer.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421716] cancer and 685,000 deaths 
globally (Sung 2021) . Acco rding to the World Health Organization, as of the end of 2020, 
there were 7.[ADDRESS_421717] 5 years, making it the world’s most prevalent cancer. HR+, defined as expression of ER and/or 
PgR, is the mo st common subtype encompassing approximately 80% of all breast cancers 
(Li 2020).  
Surgery is the cornerstone of treatment for early and locally advanced breast cancer and is 
often combined with radiation therapy and/or systemic anti -cancer therapy. In HR+ HER2 – 
breast cancer, neoadjuvant chemotherapy is used as part of SOC  to increase surgical options 
(eg, breast conservation) in patients with large tumors or lymph node involvement. Although 
the role of NET in this population is less clear, it may be used as part of SOC . NET provides 
a significantly less toxic alternative to chemotherapy that can lead to clinical responses in up 
to approximately 70% of patients (Ellis 2011 ). A meta -analysis comparing NET and 
neoadjuvant chemotherapy demonstrated no significant differences in the rates of clinical 
response and breast conservation (Spring 2016).  
In post -menopausal women with HR+  HER2 – breast cancer, AIs have shown to have 
superior efficacy compared with tamoxifen. In the P024 neoadjuvant trial of postmenopausal women with HR+ invasive breast cancer not eligible for BCS, clinical ORR was 55% for 
women receiving letrozole vs 36% for those receiving tamoxifen (p<0.001) (Ellis 2008 ). The 
proportion of women able to undergo BCS at approximately 4 months was 45% in the 
letrozole group and 35% in the tamoxifen group (p=0.022) (Ellis 2008 ). In the PROACT trial 
of postmenopausal women with operable or potentially operable locally advanced HR+ 
breast cancer, clinical ORR was 49.7% for women who received anastrozole only and 39.7% 
for those who received tamoxifen only ( odds ratio 1.50 [95% CI 0.96- 2.34], p=0.08) 
(Cataliotti 2006 ). Fo rty three percent of women on anastrozole had improvement in feasible 
surgery at baseline to actual surgery as compared to 30.8% for tamoxifen (odds r atio 1.69 
[95% CI 1.01–2.81], p=0.04) (Cataliotti 2006 ). In the IMPACT trial of postmenopausal 
women with operable or potentially operable locally advanced ER+ breast cancer, the clinical ORR was 37% for women treated with anastrozole only, 36% for tamoxifen, and 39% for 
anastrozole and tamoxif en (Smith 2005 ). The odds ratio for ORR for anastrozole vs 
tamoxifen was 1.05 (95% CI 0.61- 1.81, p=0.87) (Smith 2005). However, in women requiring 
mastectomy at baseline, 46% of women treated with anastrozole were deemed by a surgeon 
to be eligible for BCS as compared to 22% with tamoxifen (odds ratio 2.94; 
95% CI 1.11-7.81; p=0.03) (Smith 2 005). Furthermore, a pooled analysis of [ADDRESS_421718] generation AIs (anastrozole, letrozole, and vorozole) showed significant benefit of AIs over tamoxifen in clinical response rate (odds ratio 1.69, 95% CI 1.36 -2.10; 
p<0.001), and radiographic response (odds ratio 1.49; 95% CI 1.18-1.89; p<0.001) (Spring 2016) . In a pooled analysis of 4 trials of anastrozole and letrozole, AIs showed 
significant benefit over tamoxifen in radiographic response and BCS (odds ratio 1.62; 95% 
CI 1.24-2.12; p<0.001) (Spring 2016 ). 
Several trials have evaluated whether SERDs offer additional benefit compared to AIs in early breast cancer. Data generated on fulvestrant suggest similar Ki -67 reduction, clinical 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 29 
 response, and safety profile compared to AIs in in the pre -surgical setting (Lerebours 2016; 
Ma 2020; Quenel -Tueux 2015; Robertson 2013) . Two novel oral SERDs have been 
evaluated in the pre -surgical setting: AZD9496 and giredestrant. In a WOO study, AZD -9496 
(no longer in clinical development) was tolerable but did not show improved Ki -67 reduction 
compared to fulvestrant , which may be attributable to suboptimal exposure 
(Robertson 2020) . Giredestrant showed a tolerable safety profile and improved Ki -67 
reduction compared to anastrozole ( reduction from baseline to Week 2 geometric 
mean=80%, 95% CI : −85% - −72% vs 67%, 95% CI : −75 - −56% ; p=0.0222) 
(Hurvitz 2022a ). 
2.2.1.  Clinical Overview  
[IP_ADDRESS].  ARV-471 
ARV -471 is a potent, selective, orally bioavailable PROteolysis  TArgeting Chimera 
(PROTAC®) small molecule that induces active degradation of the ER. ARV -471 is being 
developed for the treatment of patients with ER+/HER2 – locally advanced or metastatic 
breast cancer. ARV -471 works by [CONTACT_340733] E3 ligase to ubiquitinate ER; once 
ubiquitinated, ER is degraded into small peptides by [CONTACT_128767].  
The importance of ER degradation in HR+ metastatic breast cancer was established by [CONTACT_340734]-targeted agent, fulvestrant. Fulvestrant has low oral bioavailability and is administered by 
[CONTACT_80626]. In clinical trials, fulvestrant results in 40 -60% degradation of ERs 
(Robertson 2013, Robertson 2001 , Kuter 2012).  
ARV -471 is orally administered, and in nonclinical studies demonstrated potent (<1 nM) and 
robust (>90%) ER degradation, even in the presence of clinically relevant ER mutations 
(Y537S and D538G) . ARV -[ADDRESS_421719] potential advantages over fulvestrant and other 
orally available SERDs. While SERDs destabilize ER and indirectly lead to ER degradation, ARV -471 actively induces ER degradation, which may lead to less drug resistance. 
Furthermore, ARV -471 demonstrates superior tumor growth inhibition  compared to 
fulvestrant in a Y537S ESR1 mutant patient -derived xenograft (ARV -471 IB ). 
[IP_ADDRESS].1. Mechanism of Action  
ARV -471 is a hetero- bifunctional PRO TAC
® molecule that simultaneously binds ER and the 
cereblon E3 ligase complex, enabling protein- protein interactions between ER and the ligase 
complex. As a result, ER becomes poly- ubiquitinated on accessible lysine residues and, 
subsequently, undergoes targeted degradation by [CONTACT_340735]. Several nonclinical studies have been conducted to confirm the mechanism of action for ARV -471 as described in the  ARV -471 IB . A summary of the data is described below.  
In vitro data demonstrated a dose -dependent decrease in ER levels in 6 ER+ cell lines 
(MCF7, T47D, BT474, CAMA -1, ZR751, and 134 -VI). Furthermore, data from MCF7 cell 
lines provide evidence that ARV -471 degrades ERs via the proteasome by [CONTACT_340736] E3 ligase. In MCF7 cells treated with ARV -471, a half -maximal DC
50 of 0.9  nM 
was achieved with maximum ER degradation of >90%. When excess cereblon  ligand 
(lenalidomide) or proteasome inhibitor (carfilzomib) was added, no ER degradation was seen. In vitro data also demonstrated that ARV -471 decreased levels of clinically relevant 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 30 
 mutant forms of ER, Y537S and D538G, in a dose -dependent manner, similar to fulvestrant. 
In a T47D cell line background, GI 50 values were 50 nM for ER Y537S and 8 nM for ER 
D538G. 
In addition to ARV -471, its epi[INVESTIGATOR_340707], ARV -473, was assessed for ER degradation activity 
(ARV471 -[ZIP_CODE]-00- INVITRO). While both ARV- 471 and fulvestrant  reduced ER levels, 
ARV -473 did not reduce ER levels, even when tested at  μM. In an ER- dependent gene 
reporter assay (ARV471-[ZIP_CODE]-00- INVITRO), ARV- [ADDRESS_421720] activity.  
In vivo data for MCF7 xenograft mouse models demonstrated both potent ER degradation 
and tumor growth inhibition  after administration of ARV -471 by [CONTACT_27176] 28 days 
(Figure 1 ). At study termination, all doses of ARV -471 (3 mg/kg, 10 mg/kg, and 30 mg/kg 
daily) significantly reduced ER levels by >94% compared to placebo. D ose-dependent TGI 
was also observed: 85% at 3 mg/kg/day, 98% at 10 mg/kg/day, and 125% at 30 mg/kg/day. 
Figure 1 ARV- 471 Significantly Inhibits Tumor Growth and Reduces ER Levels in 
the MCF7 Xenograft Model  
 
(A) Dose -dependent inhibition of tumor growth by [CONTACT_340728] -471 in an orthotopic MCF7 mouse 
xenograft model. Female NOD/SCID mice were implanted with MCF7 cells in the mammary 
fat pad and ARV -471 administration (QD×28; PO) was initiated once the tumors reached 
200 mm3. Tumor volumes were evaluated twice per week for 28 days. ARV -471 at 3, 10, or 
30 mg/kg inhibited growth of estradiol -stimulated MCF7 xenografts (85%, 98%, and 124% 
TGI, respectively). (B) At study termination, MCF7 xenografts were harvested and the ER 
levels in the xenografts were measured by [CONTACT_340737] β- actin levels. 
At all dose levels of ARV -471, >94% loss of ER was seen by [CONTACT_37417]. 
Lastly, as described in Section  [IP_ADDRESS].[ADDRESS_421721] ER degradation in participants with wild type and 
mutant forms of ER.  

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 31 
 [IP_ADDRESS].2. Impact of Cereblon Substrates  
Since ARV -[ADDRESS_421722] on known cereblon neo- morphic substrates. In one study, overnight incubation of 
Ramos  cells with increasing concentrations of ARV -471 did not lead to degradation of 
Ikaros, Aiolos, CK1α, and GSPT1, whereas the control IMiDs with known neomorphic 
substrate degradation activity (lenalidomide and CC -885) decreased levels of these 
neo-substrat es. In another study with a cell line that expresses Sall4, a recently identified 
cereblon neomorphic substrate (Donovan 2018),  partial degradation of Sall4 was seen with 
ARV -471, whereas complete degradation of Sall4 was seen with the IMiD lenalidomide at 
the same concentration (1 µM). No evidence of ARV -471- mediated Sall4 degradation was 
observed in a different cell line. While the teratogenic effects of the thalidomide class have been linked to their Sall4 -degradation activity, no significant adverse effects due to potential 
partial loss of Sall4 are expected in the patient population included in this trial since most 
adult tissues do not express Sall4 (Tatetsu 2016).  
[IP_ADDRESS].3. Nonclinical Pharmacokinetics and Drug -Drug Interactions  
Nonclinical PK data are provided in the  ARV -471 IB . A summary of the key data is 
presented below.  
The PK profile of ARV -471 in mouse, rat, dog, and monkey was characterized by a low to 
moderate clearance (13.8 to 33.8% of hepatic blood flow), extensive tissue distributi on (2.1 
to 6.0 L/kg volume of distribution at steady state), short to moderate t
1/2 (2.1 to 8.2 hr), and 
moderate to good oral bioavailability ( 27 to 65%). 
Dose -dependent increases in ARV -471 exposure were observed when ARV -471 was 
administered as an oral solution in the mouse (10, 30, 100 mg/kg), rat (30, 100, 300 mg/kg), 
dog (15, 45, 90 mg/kg), and monkey (1 and 3 mg/kg).  
 
 
 
  
Absorption: 
Combined in vitro data suggests that ARV -471 is unlikely to be a substrate of intestinal 
efflux transporters including P -gp and BCRP. A moderate to good extent of oral absorption 
was generally obtained when ARV -471 was dosed as a solution formulation in nonclini cal 
species, despi[INVESTIGATOR_340708] (ARV -471 IB ). 
Preliminary DDI results from Study ARV -471- CPhm -[ADDRESS_421723] the PK of ARV -471 when given with a moderate 
fat, moderate calories meal.  
Metabolism and Drug- Drug Interactions : 

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421724] of CYP inhibitors/inducers or drug transporters on ARV -471 
Study ARV -471-[ZIP_CODE]-00- INVITRO, a CYP reaction phenotypi[INVESTIGATOR_48633], was conducted 
consistent with current FDA guidance (FDA Guidance 2020) . This study indicated CYP3A4 
as the principal isoform responsible for CYP metabolism of ARV -471 (accounting for 85%). 
Drugs that are inhibitors of CYP3A4 may increase the exposure of ARV -471, whereas drugs 
that are inducers of CYP3A4 may reduce the exposure of ARV -471. 
Available in vitro data suggest that ARV -[ADDRESS_421725] of ARV -471 on CYP, BCRP, and P -gp substrat es 
In vitro, ARV -471 (PF -07850327) is a reversible inhibitor of CYP2B6 with an IC 50 of 
16.0 μM. Initial DDI risk assessment based on the FDA Guidance for Industry (FDA 2020 ) 
indicated the potential for ARV -471 to inhibit CYP2B6 at clinically relevant concentrations 
associated with the 500 mg QD dose. However, subsequent mechanistic static modeling, 
using bupropi[INVESTIGATOR_340709]2B6 substrate drug, indicated a low potential for DDI due 
to ARV -471- mediated reversible inhibition of CYP2B6 at human exposures associated with 
the 500 mg QD dose. Consequently, patients enrolled in clinical trials will be allowed to receive sensitive CYP2B6 substrates or CYP2B6 substrates with narrow therapeutic indices. 
 
 
ARV -471 does not induce CYP1A2, 2B6, and 3A4 in vitro.  
Nonclinical data indicate the po tential of ARV -471 to inhibit human BCRP. However, based 
on preliminary PK and clinical data (n=8 participants receiving rosuvastatin concomitantly with ARV- 471 as described in the  ARV -471 IB ), participants enrolled in this study will be 
allowed to receive sensitive BCRP substrates or BCRP substrates with narrow therapeutic 
indices.  
Nonclinical data indicate the potential of ARV -[ADDRESS_421726] current ARV -471 IB version for additional information on ARV -471 
metabolism and potential DDIs.  

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 33 
 [IP_ADDRESS].4. Nonclinical Safety and Toxicology  
Nonclinical toxicology data is provided in the  ARV -471 IB . A few key points are 
summarized below.  
Results of hERG assays for ARV -471 were negative. The hERG IC 50 and therapeutically 
relevant human C max values for ARV -471 (using 500 mg ARV -471 QD as a reference) are 
separated by [CONTACT_2669] 69-fold. 
The [ADDRESS_421727] shown ARV -471 to be we ll 
tolerated after QD dosing up to 100 mg/kg/day in rats and 90 mg/kg/day in dogs. Across the 
studies, there were no consistent findings or patterns of effects in hematology or clinical 
chemistry. As tested in dogs, ARV -471 did not elicit any changes in EC G evaluations after 
daily dosing at 90 mg/kg/day for [ADDRESS_421728] been observed in other agents that target the ER (eg, 
fulvestrant) (US FDA Fulvestrant 2002).  
 
 
 
 
 
 
 
[IP_ADDRESS].5. C
linical Trial Data: Study ARV-471- mBC -101 
Study ARV -471- mBC -101 is an ongoing FIH Phase 1/2 open- label, dose -escalation, and 
cohort expansion clinical trial of ARV -471 given alone or in combination with palbociclib 
(IBRANCE®) in participants with ER+/HER2 – locally advanced or metastatic breast cancer. 
Preliminary analyses completed on participants in the monotherapy dose escalation portion (Part A) of the FIH study suggest a tolerable safety profile, robust pharmacodynamic activity 
(ER degradation), and evidence of early clinical ac tivity in participants who received prior 
CDK 4/[ADDRESS_421729] current ARV -471 IB version. 

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 34 
 [IP_ADDRESS].  Anastrozole 
In postmenopausal women, estrogens are mainly  derived from the action of the aromatase 
enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to 
estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in 
the cancer tissue itself can therefore be achieved by [CONTACT_9565] (Anastrozole USPI ).  
Anastrozole is a selective nsAI. It significantly lowers serum estradiol concentrations and has 
no detectable effect on formation of adrenal corticosteroids or aldosterone (Anastrozole 
USPI ). 
In the US, anastrozole is currently indicated for adjuvant treatment of postmenopausal women with hormone receptor -positive early breast cancer and first -line treatment of 
postmenopausal women with hormone receptor -positive or hormone receptor unknown 
locally advanced or metastatic breast cancer. It is also indicated for the treatment of advanced 
breast cancer in postmenopausal women with disease progression following tamoxifen 
therapy. Patients with ER -negative disease and patients who did not respond to previous 
tamoxifen therapy rarely responded to anastrozole (Anastrozole US PI).  
In the EU, anastrozole is indicated for treatment of hormone receptor -positive advanced 
breast cancer in postmenopausal women and adjuvant (add- on) treatment of hormone 
receptor -positive early invasive breast cancer  in postmenopausal women, including those 
who have received two to three years of adjuvant tamoxifen (Anastrozole European 
Medicines Agency Committee for Medicinal Products for Human Use  SmPC ). 
The dose of anastrozole is 1 mg tablet taken once a day (Anastrozole USPI ). 
Anastrozole is contraindicated in pregnant and premenopausal women. It is also 
contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any 
of the excipi[INVESTIGATOR_840] (Anastrozole USPI ). Additionally in the EU, it is specifically 
contraindicated in women who are breast feeding (Anastrozole European Medicines Agency 
Committee for Medicinal Products for Huma n Use  SmPC ). 
Serious adverse reactions with anastrozole occurring in less than 1 in 10,000 patients, are: 1) skin reactions such as lesions, ulcers, or blisters; 2) allergic reactions with swelling of the 
face, lips, tong ue, and/or throat. This may cause difficulty in swallowing and/or breathing; 
and 3) changes in blood tests of the liver function, including inflammation of the liver with 
symptoms that may include a general feeling of not being well, with or without jaundi ce, 
liver pain or liver swelling (Anastrozole USPI ). 
Common adverse reactions (occurring with an incidence of >10%) in women taking 
anastrozole included: hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, 
hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, 
insomnia, pain, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, and lymphedema (Anastrozole USPI ). 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421730] common reported adverse reaction (>0.1%) leading to 
discontinuation of therapy for both treatment groups was hot flashes, although there were 
fewer patients who discontinued therapy as a result of hot flashes in the anastrozole group (Anastrozole USPI ). 
As anastrozole lowers circulating estrogen levels it may cause a reduction in bone mineral 
density with a possible consequent increased risk of fracture. Women with osteoporosis or at 
risk of osteoporosis, should have their bone mineral density assessed as per investigator’s best medical judgement  and based on local practice guidelines.  Treatment or prophylaxis for 
osteoporosis may be initiated as appropriate and carefully monitored as per investigator’s 
judgement .  
Additional or updated information on anastrozole can be found in the most recent local 
product label.   
2.3. Benefit/Risk Assessment  
The main goals of this neoadjuvant study are to assess the biologic effects and safety of ARV -[ADDRESS_421731] -meno pausal women with treatment naïve, ER+ /HER2 – breast 
cancer, amenable to definitive surgical resection, and randomize them to pre- operative 
treatment with ARV -471 or anastrozole. To allow participants the opportunity for clinical 
response, treatment will co ntinue for approximately 5.5 months prior to surgical resection.  
NET has therapeutic potential for patients with ER+ breast cancer and is currently used as SOC  in select patients, such as post -menopausal women, or those with ER+ tumors 
(Korde 2021; Gradishar 2021)  to increase the likelihood of breast conservation. It provides a 
significantly less toxic alternative to chemotherapy  that can lead to clinical responses that are 
comparable to neoadjuvant chemotherapy (Spring 2016; Wang  2020) . Although tamoxifen 
and AIs are commonly used (Section  4.2.2 ), an optimal NET regimen has yet to be 
determined. In the neoadjuvant setting, selective ER downregulators and degraders and nsAIs 
demonstrate similar safety profiles, clinical response rates, breast conservation rates, and 
Ki-67 reduction (Lerebours 2016; Ma 2020; Quenel -Tueux 2015; Robertson 2013; Hurvitz 
2020).  
Preliminary data from the ongoing FIH study with ARV -[ADDRESS_421732] ER degradation (including in participants with ESR1 mutations), and results in clinical benefit that exceeds that of fulvestrant in participants 
previously treated with CDK 4/6 inhibitors (Hamilton 2022;  Hurvitz 2022b;  ARV -471 IB ). 
Therefore, ARV -[ADDRESS_421733] common TRAEs observed in ≥10% of patients treated 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 36 
 with ARV- 471 (monotherapy therapy Parts A and B) were fatigue, nausea, arthralgia, and hot 
flush. There were n o dose dependent increases in treatment related AEs . 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of ARV -[ADDRESS_421734]  current ARV -471 IB version, which is 
the SRSD for this study. For anastrozole, the SRSD is the anastrozole SmPC.  
Participant  safety  will be monitored closely throughout study participation (Appendix 3 ). The 
Sponsor will immediately notify the Principal Investigator [INVESTIGATOR_340710].  
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS  
Objective   Endpoints   
Primary   
Evaluate the effects of ARV -471 and 
anastrozole , respectively,  on Ki -67 
expression in tumors after 2 weeks of 
treatment  Percent  change in Ki -67 expression between baseline 
and C1D15 tumor biopsies  
Estimand: See Section  [IP_ADDRESS] . 
Secondary   
Evaluate  the safety and tolerability of 
ARV -471 and anastrozole , respectively  Incidence of all adverse events , serious adverse events , 
and adverse events  leading to study drug 
discontinuation   
Evaluate  the clinical and pathological 
response of ARV -471 and anastrozole , 
respectively  Pathologic stage, pathologic complete response ( pCR) 
rate, and modified Pre -operative Endocrine Prognostic 
Index ( mPEPI ) score at the time of surgical resection 
(C6D18 ± 14 days); rates of breast conserving therapy ; 
radiographic response of the primary tumor based on 
imaging during cycle 6; caliper -based response on 
C6D1   
Exploratory   
Evaluate  the effects of ARV -471 and 
anastrozole , respectively,  on CCCA after 2 
weeks of treatment   CCCA  (Ki67  ≤2.7%) rates at C1D15   
Evaluate ER degradation of ARV -471  Percent  change in ER protein levels between baseline 
and C1D15    
Evaluate the effects of ARV -471 and 
anastrozole , respectively,  on Ki -67, and ER 
degradation by [CONTACT_340728] -471 in tumors at the 
time of surgical resection.  Changes  in ER and Ki -67 expression between baseli ne 
and Cycle 6 surgical tumor samples; Rates of CCCA in 
the Cycle 6 surgical samples.   
Explore additional biomarkers that may be 
associated  with the effects of ARV -471 in 
tumor tissue   Additional  biomarkers may include, but are not limited 
to, PgR expression,  
  
Correlate exposure of ARV -471 with ER 
reduction   Correlate  population PK model -derived PK parameters 
(AUC, C min, Cmax) with ER reduction or other response 
parameters  

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 37 
 4. STUDY DESIGN  
4.1. Overall Design  
This is a Phase 2, open- label, randomized, non- comparative POC  study of ARV -471 or 
anastrozole in participants with ER+ /HER2 – breast cancer amenable to definitive surgical 
resection. The main goal of this study is to evaluate the biological activity of ARV -471 and 
anastrozole, respectively .  
Participants will be randomized in a 2:1 manner to receive treatment on one of two treatment 
arms for approximately 5.5 months:  
• Arm A: ARV- 471 200 mg orally, daily , and continuously until day before surgical 
resection (no later than C6D18 + 14 days)  
• Arm B: anastrozole 1 mg orally, daily , and continuously until day before surgical 
resection (no later than C6D18 + 14 days) 
Stratification will occur based on the following featu res of the participant’s breast cancer:  
• Size of primary breast tumor (T-stage): ≤2 cm, >2 to <5 cm, or ≥5 cm.  
• Ki-67 score (assessed locally): <20% or ≥20% 
Participants will have a screening biopsy, an on- treatment biopsy on C1D15 (+ 5 days), and 
surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days). 
Participants will return for follow up 30 days (+7 days) after definitive surgical resection. 
After surgery, participants will receive SOC  radiation and systemic therapy (chemotherapy, 
endocrine therapy, etc.) in accordance with local practice guidelines per the treating physician’s discretion. No participant should take study drug dispensed for the trial after 
surgical resection, and no study drug should be dispense d after surgical resection.  
Approximately 150 participants are expected to be enrolled (~100 participants in Arm A and 
50 participants in Arm B). It is estimated that this sample size will provide approximately 
120 (80 participants in Arm A and 40 participants in Arm B) participants with evaluable 
paired biopsies (screening and C1D15 biopsies) as described Section 8.6.[ADDRESS_421735]- menopausal women with newly diagnosed and treatment naive 
ER+/HER2 – breast cancer that is amenable to definitive surgical resection. Patients with 
HER2 over –expressing tumors  are excluded as these patients receive SOC  treatments that 
include HER2- targeted agents. This population selected includes participants that are 
typi[INVESTIGATOR_340711]. Participants must also have tumor that is at least 1.5 cm as 
confirmed by [CONTACT_340738] g due to biopsy requirements for this study.  
4.2.2.  Rationale for Selection of Control Arm  
In ER+ /HER2 – breast cancer, an optimal endocrine- based neoadjuvant regimen has yet to be 
established. AIs have been shown to have superior clinical activity to tamoxifen in 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421736]- menopausal women (Section 2.2). NsAIs (anastrozole, letrozole) and sAIs (exemestane) 
have similar safety profiles and have shown similar efficacy in the neoadjuvant setting. The 
Z1031 study compared anastrozole, letrozole, and exemestane as NET in post -menopausal 
women with Stage II -III HR+ breast cancer and found all treatments to be similar 
(Ellis 2011 ). The clinical response rates for anastrozole, letrozole, and exemestane were 
69.1% (95% CI, 60.1% to 77.1%), 74.8% (95% CI, 66.3% to 82.1%), and 62.9% (95% CI, 53.8% to 71.4%), respectively (Ellis 2011 ). At surgery at approximately 16 weeks, the 
geometric ch ange in Ki -67 was -78% (standard error of the mean 4%) for 
anastrozole, -81.2% (standard error of the mean 3.5%) for exemestane, and -87.1% (standard 
error of the mean 2.8%) for letrozole (Ellis 2011) . There was no significant difference in 
Ki-67 suppression between treatment arms (Kruskal -Wallis p=0.45, adjusted for three -way 
comparison) (Ellis 2011).  
Anastrozole has been used as a control arm for several recent neoadjuvant studies in breast 
cancer including the ALTERNATE, NeoMONARCH, and coopERA clinical trials. In 
randomized Phase [ADDRESS_421737] ranged from 37% to 69.1% at surgery at 3 to 6 months (Smith 2005; Cataliotti 2006 ; Lerebours 2016; Quenel -Tueux 2015; Ellis 2011). In 
these trials, the rates of BCS  for patients receiving anastrozole ranged from 43% to 57.8% 
(Smith 2005 ; Cataliotti 2006 ; Lerebours 2016; Ellis 2011) . Anastrozole has also been used in 
trials assessing Ki -[ADDRESS_421738], NeoMONARCH, and coopERA 
clinical trials. In these 4 trials of postmenopausal women with early or locally advanced HR+ 
breast cancer, Ki -67 reduction (geometric mean change) at 2 weeks ranged from -63% (90% 
CI, −73 to −49) to  -76% (95% CI -81.9 to -68.2) for patients receiving anastrozole 
(Dowse tt 2005; Smith 2005; Ellis 2011; Hurvitz 2020; Hurvitz 2022a ). Given the clinical 
activity of anastrozole in the neoadjuvant setting and thus common usage as a SOC  and 
control arm, it was chosen as the control arm for this study.  
4.2.3.  Rationale for Duration of Treatment  
All participants will be treated with NET for approximately 5.[ADDRESS_421739] been used by [CONTACT_340739]+ /HER2 – breast cancer 
(Guerrero -Zotano 2017; Barchiesi 2020; Martí 2021).  
4.2.4.  Collection of Retained Research Samples  
Retained research samples will be collected and stored for further analyses which may, for 
example, provide greater understanding of the study intervention. 
4.3. Justification for Dose  
4.3.1.  ARV-471 
In the FIH monotherapy dose escalation study, ARV -471- mBC -101, no DLTs were 
observed, and an MTD was not reached. The MAD was 700 mg (administered at 400 mg in 
the morning and 300 mg in the evening in 3 of the 4 participants to lessen pi[INVESTIGATOR_13551]). Two 
RP2Ds, 200 mg daily and 500 mg daily, were selected for Phase 2 evaluation in the ongoing 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421740] cancer. Both doses resulted in steady state C max 
and AUC 24 values that significantly exceeded thresholds associated with tumor regression in 
nonclinical models, eg, MCF7 -tumor bearing NOD/SCID mice treated at 30 mg/kg. Both 
doses are also below the NOAEL of 100 mg/kg/day in female rats (the most sensitive species 
in nonclinical toxicology studies), which is equivalent to a human dose of approximately 
960 mg daily. Ad ditionally, both doses had an acceptable safety profile, and ER degradation 
was demonstrated in participants across all doses in which paired biopsies were obtained.  
In Part B monotherapy expansion, no meaningful differences were noted between the 200 mg 
and 500 mg dose levels in overall safety, such as TRAEs, TEAEs  leading to discontinuations, 
or dose interruptions (Hurvitz 2022b). Clinical benefit (as measured by [CONTACT_234703])  was seen at 
both doses w ith no clear differences observed between the 200mg and 500mg dose levels . No 
significant dose -response relationship was seen between the 200 mg and 500 mg daily doses 
in a heavily pretreated population.  
Considering the benefits and risks in this early stage curable population, a 200- mg dose of 
ARV -471 was selected for this study based on the totality of safety, PK, PD, and efficacy 
data available from Part A dose escalation and backfill and Part B expansion of the FIH study 
as of 06 June 2022  (Hurvitz 2022b;  ARV -471 IB ). 
4.3.2.  Anastrozole 
The approved dose and schedule of anastrozole will be used per the USPI (or local label).  
4.4. Safety Review Committee  
The SRC will review all data from participants enrolled in this study. The SRC will be 
responsible for making recommendations as to whether it is scientifically and ethically appropriate to continue enrollment, discontinue treatment groups, or stop the study.  
The SRC membership, will be co mprised of selected study principal investigators and 
Sponsor representative(s). The SRC is responsible for reviewing and evaluating data at least 
every three months.  
4.5. Start and End of Study Definition  
The start of the trial is defined as the first particip ant’s first visit. End of study is defined as 
the last participant’s last study visit or follow -up phone call. Study completion is defined as 
the final date on which data for the primary endpoint was or is expected to be collected, if 
this is not the same.  
5. STUDY POPULATION 
This study can fulfill its objectives only if appropriate participants are enrolled. The following eligibility criteria are designed to select participants for whom participation in the 
study is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this protocol.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 40 
 Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is  not permitted.  
5.1. Inclusion Criteria  
Participants for whom neoadjuvant e ndocrine monotherapy is deemed appropriate are 
eligible to be included in the study only if all of the following criteria apply:  
Age and Sex:  
1. Post-menopausal females ≥18 years  
• Post-meno pausal status will be defined by [CONTACT_37408]: prior 
bilateral oophorectomy, age ≥60, or age <[ADDRESS_421741] 
12 months (in the absence of chemotherapy, tamoxifen, toremifene, ovarian 
suppression, or any additional medical intervention that may have induced 
amenorrhea) and FSH/estradiol in the postmenopausal range  
Type of Participant and Disease Characteristics:  
2. Histologically or cytologically confirmed ER+ and HER2 – breast cancer (per local 
assessment). ER and HER2 status must be documented:  
• ER+ disease, with ER staining of ≥10% of tumor cell nuclei by [CONTACT_340729]/CAP Guidelines (Allison 2020) .  
• HER2 – disease by [CONTACT_340740]/CAP guidelines  
• Ki 67 score ≥5%, analyzed locally  
3. Clinical T1c -T4c, N0 -N2, M0 breast cancer amenable to definitive surgical resection, 
without bilateral  breast ductal carcinoma in situ or invasive breast cancer  
4. The primary tumor must be at least 1.5 cm by [CONTACT_9661]  
5. Willingness to undergo a screening biopsy, an on- treatment biopsy and surgical 
resection  
Informed Consent:  
6. Capable of giving signed informed consent as described in Appendix 1,  which 
includes compliance with the requirements and restrictions listed in the informed consent and in this protocol.  
Other Inclusion Criteria :  
7. ECOG PS 0 or 1.  
8. Adequate Bone Marrow Function, defined as (with no transfusion of blood products or use of hematopoietic growth factors in the 28 days prior to enrollment):  
• ANC ≥1,500/mm
3 or 1.5 × 109/L; 
• Platelets ≥100,000/mm3 or 100 × 109/L; 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 41 
 • Hemoglobin ≥9 g/dL. 
9. aPTT  ≤1.25  × ULN and INR  ≤1.25 
• Unless the participant is receiving anticoagulation, then aPTT and INR should be 
within the therapeutic range of the intended use.  
10. Adequate renal function defined as serum creatinine of ≤1.5  × ULN or an estimated 
creatinine clearance of ≥60 mL/min by [CONTACT_79423]  
11. Adequate liver function , defined as:  
• Total serum bilirubin of ≤1.5 × ULN unless the participant has documented 
Gilbert syndrome. Participants with Gilbert syndrome must have total serum bilirubin ≤3 × ULN.  
• AST and ALT of ≤2.5  × ULN  
12. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the  following criteria apply:  
Medical Conditions:  
1. Any other active malignancy within 3  years prior to enrollment, except for adequately 
treated basal cell or squamous cell skin cancer, or cervical carcinoma in situ.  
2. Any of the following in the previous 6 mont hs:  
• Myocardial infarction  
• Severe unstable angina  
• Coronary/peripheral artery by[CONTACT_9292]  
• Symptomatic congestive heart failure ([LOCATION_001] Heart Association class III or IV)  
• Cerebrovascular accident  
• Transient ischemic attack  
• Symptomatic pulmonary embol ism or other clinically significant epi[INVESTIGATOR_340705] 
3. Any of the following in the previous 6 months:  
• Congenital long QT syndrome  
• Torsade de Pointes  
• Sustained ventricular tachyarrhythmia and ventricular fibrillation  
• Left anterior hemiblock (bifascicular block)  
• Ongoing cardiac dysrhythmias of NCI Common CTCAE ≥Grade 2  
• Atrial fibrillation of any grade (≥Grade 2 in the case of asymptomatic lone atrial fibrillation)  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 42 
 4. Active inflammatory GI disease, chronic diarrhea, known uncontrolled diverticular 
disease or previous gastric resection or lap band surgery.  
5. Cirrhosis meeting criteria for Child Pugh B and C  
6. Major surgery (as defined by [CONTACT_737]) within four weeks of first dose of study 
drug  
7. History of allergy or reaction to any of the drug components for ARV -[ADDRESS_421742] ase deficiency or glucose -galactose malabsorption. 
8. Inability to take oral medication without crushing, dissolving, or chewing tablets  
9. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality that may increa se the risk 
of study participation or, in the investigator’s judgment, make the participant 
inappropriate for the study.  
Prior/Concomitant Therapy:  
10. Prior treatment for breast cancer including systemic therapy ( eg, chemotherapy, 
hormonal therapy), radiation, surgery, or any investigational agents.  
11. Any live vaccines within [ADDRESS_421743] dose of study drug.  
12. Taking the following agents within 14 days of C1D1 unless otherwise specified:  
• Sensitive P -gp substrates or P -gp substrates with nar row therapeutic indices  
• Strong CYP3A4 inhibitors or inducers  
• Any medications with known QT risk, and/or are associated with a risk of 
Torsades de Pointes, within 7 days of C1D1  
Diagnostic Assessments:  
13. QTcF >470 msec 
14. Participants with active, uncontrolle d bacterial, fungal, or viral infection, including 
(but not limited to) HBV, HCV, and known HIV or AIDS -related illness.  
Other Exclusions:  
15. Participants who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to 
continue as a participant. Strict conditions apply and Sponsor approval is required.)  
16. Participants who are compulsorily detained for treatment of either a psychiatric or 
physical (eg, infectious disease) illn ess. 
17. Investigator site staff or Sponsor employees directly involved in the conduct of the 
study, site staff otherwise supervised by [CONTACT_093], and their respective family 
members.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 43 
 5.3. Lifestyle Considerations  
Restrictions regarding lifestyle, activities , and/or diet required for study eligibility and/or 
participation are listed below. Participants will be instructed by [CONTACT_340741]: 
• ARV -471 should be taken together with food at approximately the same time in the 
morning. Additional in structions on how to take ARV -471 is described in Section 6.1.  
• Participants should not consume grapefruit juice as it may interact with ARV -471. 
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failu re participants, to meet the CONSORT publishing 
requirements, and to respond to queries from regulatory authorities. Minimal information includes date of consent, demography, screen failure details, eligibility criteria, and any AEs 
and SAEs.  
Individuals w ho do not meet the criteria for participation in this study (screen failures) must 
be indicated as such in the IRT system.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened up to 2 times.  
5.4.1.  Re-testing  During Screening  
Re-testing of laboratory parameters and/or other assessments within the Screening period 
will be permitted (in addition to any parameters that require a confirmatory value).  
The most current result prior to enrollment is the value by [CONTACT_192236] h study inclusion will be 
assessed, as it represents the participant’s most current clinical state.  
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study procedure(s) intended to be administered to a study 
participant according to the study protocol.  
For the purposes of this protocol, study intervention refers to ARV -471 and anastrozole.  
Other medications used as support or escape medicati on for preventative, diagnostic, or 
therapeutic reasons, as components of the SOC  for a given diagnosis, may be considered as 
non-IPs. 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421744] 
Description/
Class and 
Dosage 
Form  Potency  IP/ 
Non-IP  Appearance  Packaging and 
Labelling  Storage Conditions  
(per label)  
ARV-471 
tablets  100 mg  IP White to 
off-white 
oval tablet IP will be 
provided in a 
high-density 
polyethylene 
bottle with child-
resistant cap. 
Each bottle will 
be labelled as 
required per 
local regulations.  ARV-471 Patient Bottle Supply 
(30 count):  
Store unopened bottle at 2°C to 
8°C (36°F to 47°F). Once a bottle 
is opened, it may be stored at 
temperatures up to 25°C (77°F) 
for [ADDRESS_421745] from light.  
Anastrozole 
tablets  1 mg  IP See Pharmacy Manual for full description and Section  6.2 
The label text of the study treatments will comply with Good Manufacturing Practices and national legislation to meet 
requirements of the participating sites/countries.  
6.1. Study Intervention(s) Administered  
6.1.1.  Administration  
Participants will be randomized to one of two treatment arms and will receive study drug for 
approximately 5.5 months prior to undergoing surgical resection (Table 5). If surgical 
resection is delayed for non- study drug related reasons, study drug may be continued beyond 
C6D18 (+14 days) only after discussion with the Medical Monitor. No participant should 
take study drug dispensed for the trial after surgical resection, and no study drug should be 
dispensed after surgical resection.  
Table 5 Study Treatment  
Arm  Study Drug Daily 
Dose  Frequency  Route of Administration  
A ARV-471 200 mg  Daily and continuously until day 
before  surgical resection, but no 
later than C6D18  (+14 days)  Oral 
B Anastrozole 1 mg  Daily and continuously until day 
before surgical  resection, but no 
later than C6D18  (+14 days)  Oral 
A cycle is defined as 28 days. If a treatment interruption continues beyond Day 28 of the 
current cycle, then the day treatment is restarted will be counted as Day 1 of the next cycle. 
Procedures required as per SoA on Day 1 of the given cycle will be performed when study 
treatment is resumed.  
[IP_ADDRESS].  Arm A  
Participants in Arm A will use 100 mg strength tablets of ARV -471. 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 45 
 • ARV -[ADDRESS_421746] not be crushed, chewed, or dissolved.  
• ARV -471 should be taken on the day of biopsy and the day the pre -surgical study 
labs are collected.  
• ARV -471 should be administered until the day before surgical resection (no later than 
C6D18 +  14 days). 
Participants taking ARV -471 will self -dose, except for scheduled clinic visits  when 
ARV -471 should be withheld and taken while in the clinic ( ie, not at home) under the 
supervision of study staff.  
[IP_ADDRESS].  Arm B  
Participants in Arm B will use 1 mg strength tablets of anastrozole.  
• Anastrozole should be taken by [CONTACT_340742].  
• Anastrozole should be taken on the day of biopsy and the day the pre -surgical study 
labs are collected.  
• Anastrozole should be administered until the day before surgic al resection (no later 
than C6D18 +  14 days). 
• Additional information on anastrozole can be found in the locally approved product label.  
6.2. Preparation, Handling, Storage and Accountability  
• The IP should be stored in a secure area according to local regulations. It is the 
responsibility of the Investigator to ensure that IP is only dispensed to study 
participants. The IP must be dispensed only from official study sites by [CONTACT_20443].  
• The IP storage manager should ensure that the study treatment is stored in accordance 
with the environmental conditions (temperature, light, and humidity) as determined by [CONTACT_340726]. If concerns regarding the quality or appearance of the study treatment 
arise, the study treatment should not be dispensed, and Arvinas should be 
immediately contact[INVESTIGATOR_530].  
• Study treatment not supplied by [CONTACT_340743].  
• IP documentation (whether supplied by [CONTACT_340744]) must be maintained that 
includes all processes required to ensure study treatment is accurately administered. 
This includes documentation of IP storage, dispensing processes, and administration.  
• Further guidance and information for final disposition of unused study treatment are provided in the study Pharma cy Manual.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421747] until the next scheduled clinic visit by [CONTACT_6606].  
At each visit the participant should bring all bottles/cartons of IP a long with their participant 
dosing diary for review by [CONTACT_7893].  
The number of tablets in each bottle/carton should be recorded before dispensing and on 
return of bottles/cartons.  
6.2.2.  Clinical Product Complaints  
A Clinical Product Complaint is defined as  a problem or potential problem with the physical 
quality or characteristics of clinical drug supplies used in a clinical research study sponsored 
by [CONTACT_340726]. Any product complaint associated with an IP supplied by [CONTACT_340745].  
6.3. Assignment to Study Intervention  
This is an open- label randomized study. Randomization will be 2:1, and stratification will 
occur based on the following features of the participant’s breast cancer:  
• Size of primary breast tumor (T-stage): ≤2 cm, >2 to <5 cm, or ≥5 cm.  
• Ki-67 score (assessed locally): <20% or ≥20% 
Once screened, the participant will be registered in the IRT system to obtain the participant ID number. Study site users will receive log -in information and directions on how to access 
the IRT system. Specific instructions for using the IRT will be provided to the investigational 
site in a separate document.  
6.4. Study Intervention Compliance  
Treatment compliance will be monitored by [CONTACT_53973] y as well as the participant’s 
medical record and eCRF.  
Noncompliance is defined as taking less than 80% (providing no required dose interruptions 
occurred) or more than 120% of assigned study drug during any evaluation period. 
For participants receiving ARV -471 (Arm A):  
ARV -471 will be administered orally daily with food during each 28- day cycle. On days of 
scheduled clinic visits, study drug treatment should be withheld and taken while in the clinic 
(ie, not at home) under the  supervision of study staff. Participants will self -dose as described 
above, with the exception of doses that will be administered at the clinic.  
At each visit where additional study drug will be dispensed, the previously dispensed study 
treatment will be retrieved by [CONTACT_340746]. Participants will be 
required to return all bottles and remaining tablets of ARV -471, as well as the completed 
participant diary for drug accountability and compliance. Participants are to complete the  
study drug diary daily during study participation; documentation of food consumption is 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 47 
 required for C1 only. Participants exhibiting poor compliance as assessed by [CONTACT_340747].  
For participants receiving anastrozole (Arm B):  
Anastrozole will be administered orally daily during each 28- day cycle.  
At each visit where additional study drug will be dispensed, the previously dispensed study 
treatment will be retrieved by [CONTACT_340746]. Participants will be 
required to return all bottles and remaining tablets of anastrozole, as well as the completed participant diary for drug accountability and compliance. Participants are to complete  the 
study drug diary daily during study participation. Participants exhibiting poor compliance as assessed by [CONTACT_340748].  
6.5. Dose Modification and Treatment Discontinuati on 
The medical monitor or designee must be notified of any hold or dose modification of study 
drug. See  Appendix [ADDRESS_421748] improved enough to 
allow a safe surgery per the treating investigator.  
Dosing for any individual participant may be interrupted ( ie, treatment may be temporarily 
held) if the participant experiences an AE that, in the opi[INVESTIGATOR_12182]’s 
medical representative, warrants a dose interruption for that participant’s wellbeing. Dosing 
must be interrupted for certain criteria as discussed in Section s 6.5 and 7. Prior to 
re-initiating study drug in a participant with a dosing interruption lasting >[ADDRESS_421749] be consulted. Periodic study visits to assess saf ety 
and laboratory studies should also continue as scheduled or more frequently if clinically indicated during such dosing interruptions. If a participant’s treatment is interrupted for more 
than [ADDRESS_421750] be permanently discontinued.  
6.5.1.  ARV-471 
• All Grade 4 AEs related to ARV -471 and considered to be clinically significant per 
treating investigator  require permanent discontinuation of ARV -471. 
• For any Grade [ADDRESS_421751] be permanently discontinued.  
• For all ARV -[ADDRESS_421752] their dose interrupted until the AE returns to ≤Grade 1 or 
baseline. Dose reduction should occur per  Table 6 . 
o Participants may resume treatment in the presence of Grade 2 fatigue. 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 48 
 • For all treatment -related Grade [ADDRESS_421753] 
their dose interrupted until AEs retu rn to Grade ≤2 or baseline. Dose reduction should 
occur per  Table 6. 
• In the event of QTcF prolongation (regardless of causality), possible alternate 
reversible causes (eg, electrolytes, concomitant medications) should be evaluated. If 
reversible causes are identified, they should be corrected accordingly. If reversible 
causes are not identified, dose adjustments may be required as described below.  
o Grade 1: no adjustments or additional monitoring is required.  
o Grade 2: no adjustments are required. If the QTcF remains above 480 msec for 
more than 2 cycles or if Grade 2 QTcF prolongation recurs in the absence of other 
alternative causes or despi[INVESTIGATOR_4574], dose adjustment 
and/or discontinuation should be considered in consultation with a cardiologist 
and the study medical monitor, taking into account the most current ARV -471 IB 
version, the emerging safety data from ARV -471 trials and the Investigator’s best 
medical judgment. Initiate more frequent ECG monitoring per PI [INVESTIGATOR_340712] ≤480 msec or ≤60  msec change from baseline.  
o Grade 3: withhold ARV -471 treatment until Grade ≤2. If an alternate reversible 
cause is identified  and addressed , resume treatment at the same dose level. If a 
reversible cause is not identified, reduce ARV -471 by 1 dose level. Initiate more 
frequent ECG monitoring per PI [INVESTIGATOR_340713] ≤480 msec or ≤60  msec 
change from baseline.  
o Grade 4: permanently discontinue all study treatment.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 49 
 Table 6 Dose Reduction – Guidance for Adverse Events Related to ARV -471 (Except 
QTcF Prolongation)  
6.5.2.  Anastrozole 
Please refer to the current anastrozole approved local product labeling for a summary of the 
expected safety profile in participants with HR+/HER2− breast cancer, including a full list of all Warnings and Precautions.  
• Dose modification of anastrozole is not allowed.  
• For Grade [ADDRESS_421754] 
cancer.  
6.7. Treatment of Overdose 
For this study, any dose of ARV -471 greater than 200 mg daily will be considered an 
overdose. 
Sponsor does not recommend specific treatment for an overdose.  
In the event of an overdose, the Investigator or qualified designee should:  
1. Contact [CONTACT_22840] [ADDRESS_421755] dose reduction  Reduce to 100 mg per dayb, c 
Second dose reduction  Discontinue ARV -471 
Any Grade  4 AE related to ARV -471 or  any Grade 3 
related to ARV -471 thromboembolic event s or 
cardiovascular event s Discontinue ARV -471 
Abbreviations : AE=adverse event  
a. Grade 3 AEs related to ARV -471 that do not require dose reduction:  
• Grade 3 fatigue lasting ≤7 days  
• Grade 3 lymphopenia lasting <72 hours  
• Grade 3 nausea/vomiting/diarrhea lasting ≤[ADDRESS_421756] instance of the related Grade 3 AE or intolerable Grade 2 AE 
c. If the participant had a related Grade 2 intolerable AE, and the AE was rapi[INVESTIGATOR_1920], and redosing 
is not expected to pose a significant risk to the participant, one dose re -escalation of ARV -471 may be 
considered after consultation with the Medical Monitor .  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 50 
 2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half -lives or 28 calendar days after the overdose of ARV -471 (whichever is 
longer).  
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.  
4. Overdose is reportable to the sponsor only when associated with an SAE.  
5. Obtain a blood sample for PK analysis if requested by [CONTACT_7195] 
(determined on a case-by- case basis).  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_340749].  
There is no known antidote for anastrozole overdose. General supportive measures should be taken (refer to anastrozole local product label).  
6.8. Prior and Concomitant Therapy  
Any vaccine (see COVID information in  Appendix 9)  or medication  (Appendix 8 ), including 
over the counter or prescription medicines, vitamins, physiologic replacement doses of 
systemically administered corticosteroids, and/or herbal supplements that the participant is  
receiving at the time of enrollment (within 28 days before the time of enrollment) or receives 
during the study must be recorded in the eCRF along with:  
• Reason for use.  
• Dates of administration including start and end dates.  
• Dosage information including dose and frequency.  
The Medical Monitor should be contact[CONTACT_63193].  
Herbal supplements are not recommended . Other concomitant medications may be 
considered on a case-by- case basis by [CONTACT_340750], as necessary.  
6.8.1.  Prohibited Therapy  
Known prior medications that exclude a participant from participating in the study are described in the exclusion criteria (Section  5.2). 
[IP_ADDRESS].  ARV-471 
Participants enrolled in this clinical study receiving ARV -471 will not be allowed to receive 
the following medications , food or herbal supplements  (Appendix 8) . Unless otherwise 
specified, these substances  should be discontinued at least 14 days prior to starting ARV -471. 
• Strong inducers/inhibitor s of CYP3A4  
• Sensitive P -gp substrates or those with narrow therapeutic indices  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 51 
 • Any medications that are known to prolong the QT interval, and/or are associated 
with a risk of Torsades de Pointes, within [ADDRESS_421757] dose of ARV -471 and 
during the study, unless they are being used with caution to treat a drug- related AE 
when no alternative is available.  
Co-administration of gastric acid -reducing agents may reduce ARV -471 absorption. The 
concomitant use of PPIs with ARV -471 is not recommended. If PPI  [INVESTIGATOR_340714], 
ARV -471 drug intake with a moderate -fat meal (400 -800 calories, approximately 35% fat) is 
recommended.  
H2 blockers (eg, cimetidine, famotidine) or local antacids (eg, aluminum hydroxide, calcium 
carbonate, bismuth subsalicylate) may  be used. Administer ARV -471 ≥2 hours before or 
after antacids. Administer ARV -471 ≥ [ADDRESS_421758] current ARV -471 IB version.  
[IP_ADDRESS].  Anastrozole 
Participants enrolled in this clinical study receiving anastrozole will not be allowed to receive medications that are excluded in the anastrozole USPI [INVESTIGATOR_340715]. Please refer to the USPI 
[INVESTIGATOR_340716].  
[IP_ADDRESS].  Other Prohibited and/or Limited use of Anti -tumor/Anti -Cancer or 
Experimental Drugs, or Procedures  
• Other therapi[INVESTIGATOR_340717] -cancer effects  (including radiation therapy)  are 
prohibited on study prior to surgical resection.   
6.8.2.  Other Restrictions and Precautions  
Participants are not allowed to consume grapefruit juice while receiving ARV -471. Study 
drugs should be administered as per Section 6.1. Other lifestyle restrictions are described in 
Section  5.3.  
Participation in any interventional or non- interventional investigational studies should be 
discussed with the Medical Monitor.  
6.8.3.  Supportive Care  
Palliative and supportive care for disease related symptoms may be administered at the 
investigator’s discretion and according to the specific supportive care product Prescribing Information or the current ASCO guidelines.  
6.9. Surgical Resection  
Participants should undergo definitive surgical resection approximately 5.5 months after 
starting study treatment (C6D18 ± 14 days). 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421759] local guidelines as agreed upon by 
[CONTACT_340751]. Pathological staging (ypT, ypN) must be performed on the 
resected sample and must be available for data entry and monitoring.  
During the week preceding surgical resection, if a participant experiences any AE that may 
be related to study drug and may impact surgical risk as per the treating physician, study drug 
should be discontinued (if applicable) and surgery should be delayed unt il AEs have 
improved enough to allow a safe surgery per the treating investigator.  
After surgery, participants will receive SOC  radiation and systemic therapy (chemotherapy, 
endocrine therapy, etc.) in accordance with local practice guidelines per the treating 
physician’s discretion.  
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Criteria for Stoppi[INVESTIGATOR_340718], either in its entirety or at any study site, for reasonable caus e provided that written notice is submitted in advance of the intended 
termination. The Investigator may also terminate the study at his/her site for reasonable cause, after providing written notice to the Sponsor in advance of the intended termination. 
Advance notice is not required by [CONTACT_26257]. 
If the Sponsor terminates the study for safety reasons, the Sponsor will immediately notify the Investigator by [CONTACT_340752].  
The Sponsor (and/or regulatory agency) reserves the right to discontinue the study for medical and/or administrative reasons at any time.  
Conditions that may cause termination of the study in its entirety or an individual study site 
may include but are not limited to:  
• The discovery of an unexpected, serious, or unacceptable risk to any participant 
enrolled in the study.  
• The Sponsor’s decision to suspend or discontinue further testing or evaluation of the 
drug under study.  
• The fai lure of the Investigator to comply with the approved protocol, appropriate 
guidelines, and applicable regulations.  
• Submission of intentionally or knowingly false information from the Investigator to 
the Sponsor.  
7.2. Discontinuation of Study Intervention  
It may  be necessary for a participant to permanently discontinue study intervention.  Reasons 
for permanent discontinuation of study intervention may include the following:  
• Significant global deterioration of health status requiring discontinuation;  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 53 
 • Objective dis ease progression, or occurrence of a second malignancy that requires 
systemic therapy or radiotherapy for treatment.  
• Unacceptable toxicity and/or AE warranting discontinuation of ARV -471 or 
anastrozole as described in Section  6.5. 
• Significant protocol violation;  
• Loss of ability to freely provide consent through imprisonment or involuntarily 
incarceration for treatment of either a psychiatric or physical (eg, infectiou s disease) 
illness.  
• Lost to follow -up; 
• Participant refused further treatment;  
• Study terminated by [CONTACT_3211];  
• Death;  
Note that discontinuation of study intervention does not represent withdrawal from the study. 
If study intervention is permanently discontinued, the participant will remain in the study to 
be evaluated for protocol specified follow -up procedures as outlined in the SoA 
(Section  1.3). The o nly exception to this requirement is when a participant withdraws consent 
for all study procedures including post -treatment study follow -up or loses the ability to 
consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either a 
psychiatric or physical illness).  
In the event of discontinuation of study intervention, it must be documented on the appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of study intervention or also from study procedures, posttreatment study follow -up, 
and/or future collection of additional information.  
7.3. Participant Discontinuation/Withdrawal From the Study  
A participant may withdraw from the study at any time at their own request. Reasons for 
discontinuation from the study may include:  
• Refused further study procedures;  
• Lost to follow -up; 
• Death;  
• Study terminated by [CONTACT_3211].  
The participant will be permanently discontinued from the study intervention and the study at 
that time.  
If the participant withdraws from the study and also withdraws consent (Section 7.3.1 ) for 
disclosure of future information, no further evaluations should be performed and no additiona l data should be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421760] with him or her or persons previously authorized by [CONTACT_19983]. Participants should notify the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records by [CONTACT_093], as to whether  the withdrawal is 
only from further receipt of study intervention or also from study procedures and/or posttreatment study follow -up, and entered on the appropriate CRF page. If vital status 
(whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with 
local law.  
7.4. Lost to Follow -Up  
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. All reasonable efforts must 
be made to locate participants to determine and report their ongoing status. This includes 
follow- up with persons authorized by [CONTACT_2299]. Lost to follow -up is defined by [CONTACT_250980] a minimum of three documented phone calls, faxes, or emails as well as lack of response by [CONTACT_121032]. All attempts 
should be documented in the participant’s medical  records  
The following actions must be taken if a participant fails to return to clinic for a required study visit:  
• The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_263403] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
• The site staff and representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated c ontact information.  
• If investigator’s use of third- party representative to assist in the follow -up portion of 
the study has been included in the participant’s informed consent, then the investigator may use a Sponsor -retained third -party representative to assist site staff 
with obtaining participant’s contact [CONTACT_340753] -up portion of the study.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 55 
 • If it is determined that the participant has died, the site will use permissible local 
methods to obtain date and cause of death.  
• If after all attempts, the participant remains lost to follow -up, then the last known 
alive date as determined by [CONTACT_148693]’s medical records.  
8. STUDY ASSESSMENTS AND PROCEDURES  
The in vestigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study- specific procedures.  
Study procedures and their timing are summarized in the SoA ( Section  1.3). Protocol  waivers 
or exemptions (including but not limited to eligibility) are not allowed.  
Safety issues should be discussed with the sponsor immediately upon occurrence or 
awaren ess to determine whether the participant should continue or discontinue study 
intervention. 
Adherence to the study design requirements, including those specified in the SoA 
(Section  1.3), is essential and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the SoA (Section  1.3). 
Every effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform 
the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely  manner.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].  
Additional measures, including non- study required laboratory tests, should be performed as 
clinically indicated or to comply with local regulations. Laboratory toxicities (eg, suspected drug- induced liver enzyme evaluations) will be monitored during the follow -up phase via 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 56 
 on-site/local labs until all study drug related toxicities resolve, return to baseline, or are 
deemed irreversible.  
Some of the assessments referred to in this section may not be captured as data in the eCRF. 
They are intended to be used as safety monitoring by [CONTACT_1963]. Additional 
testing or assessments may be performed as clinically necessary or where required by [CONTACT_53933].  
8.1. Efficacy Assessments  
8.1.1.  Disease Response Assessment  
[IP_ADDRESS].  Imaging and Clinical Assessment  
To meet the study’s exploratory objectives related to assessment of anti -tumor response, 
preliminary antitumor activity of ARV -471 and anastrozole , respectively,  will be evaluated 
through tumor assessment imaging, tumor measurement on physical exam, and assessment of 
pathologic stage/resi dual disease. Study evaluations will take place in accordance with the 
SoA (Section  1.3). 
[IP_ADDRESS].  Radiographic Imaging  Assessment  
Radiographic imaging ( eg, breast ultrasound, breast MRI with contrast, and/or mammogram) 
is required during Screening, C4D1,  and prior to surgical resection. Contrast enhanced breast 
MRI is the preferred imaging modality. The same imaging method used at baseline must also 
be used at all post baseline imaging visits (ie , C4D1, within [ADDRESS_421761] tumor). 
Breast  imaging conducted as part of the participant’s routine clinical manage ment ( eg, 
ultrasound, MRI, mammogram) and obtained before signing of the ICD may be utilized for Screening or baseline purposes provided the procedures met the protocol -specified criteria 
and were performed within the time frame defined in the SoA  (Section  1.3). Full staging 
scans during or prior to screening may be performed, if necessary, at the discretion of the investigator as per SOC .  
Tumor imaging response assessment will be performed according to modified RECIST 1.[ADDRESS_421762] 1.5 cm (15 mm)  
in the longest diameter . Additional lesions identified on breast imaging may be followed for 
response as outlined in Appendix 11 .  
[IP_ADDRESS].  Physical Exam: Caliper -based Measurements  
Caliper based measurements of the primary breast tumor must be performed in accordance 
with the SoA (Section  1.3). 
[IP_ADDRESS].  Local Pathological Assessment of Tissue from Surgical Resection  
Local pathological assessment of the tissue from surgical resection (performed after 
approximately 5.5 months of treatment), at minimum, should include pathologic stage (ypT 
and ypN stage) as described in the Laboratory Manual. Pathologic complete response  will be 
defined as the absence of residual invasive cancer on evaluation of the complete breast 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 57 
 specimen and all sampled regional lymph nodes following completion of neoadjuvant 
systemic therapy (ie, ypT0/T is ypN0 in the current AJCC staging system).  
8.2. Safety Assessments  
Safety will be evaluated through AE monitoring, clinical evaluations (ie, vital signs, physical 
exams, ECGs), and laboratory tests (ie, hematology, serum chemistries).  
Any clinically significant changes, in the opi[INVESTIGATOR_689], noted during abbreviated or final physical examinations, ECG evaluations, and any other safety 
assessments, whether or not these procedures are required by [CONTACT_760], should also be 
recorded in the appropriate AE page of the eCRF, including information regarding NCI 
CTCAE v5.0 grade, relationship to study drug, any action taken, date of onset and outcome  
Appendix 3.  
Planned time points for all safety assessments are provided in SoA (Table 2 ). Unscheduled 
clinical laboratory measurements may be obtained at any time during the study to assess any 
perceived safety issues.  
8.2.1.  Physical Examinations  
A complete physical examination will include, at a minimum, assessments of the breasts, 
neck/axillary lymph nodes, cardiovascular, respi[INVESTIGATOR_696], GI , and musculoskeletal systems. An 
abbreviated physic al examination will be symptom directed.  
The physical examination should be performed by [CONTACT_340754]. 
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
Physical examinations may  be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation.  
Physical examination findings collected during the study will be considered source data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3)  must be reported according to the processes in 
Sections  8.3.1  to 8.3.4 . 
8.2.2.  Vital Signs  
Temperature assessments may be oral or tympanic. BP and pulse measurements will be 
assessed while the participant is in a sitting position or semi recumbent position 
(recommended ). The same position should be used throughout the study. Manual techniques 
will be used only if an automated device is not available.  
BP and pulse measurements should be preceded by [CONTACT_340755] a quiet setting  without distractions (eg, television, cell phones).  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 58 
 8.2.3.  Electrocardiograms  
Screening ECGs will be single 12- lead ECGs and are not required to be obtained on vendor 
machines. Starting at C1D1  (pre-dose, baseline) , triplicate [ADDRESS_421763] 5 minutes in a supi[INVESTIGATOR_2547]. Triplicate ECGs are defined as three consecutive ECGs 
performed approx imately 2 minutes apart but within 10 minutes for all 3 measurements as 
per Table 2  to determine the QTc interval.  
All triplicate ECG tracings will be sent electronically to a central ECG laboratory for manual  
interval measurements. The final ECG reports from the central ECG laboratory should be maintained  in the participant's source documentation.  
All ECG’s must be reviewed by [CONTACT_340756], including verifying that the 
machine reading  is accurate, and that the Fridericia correction formula is applied.  
If vendor ECG machine readings return a n abnormal ECG finding considered clinically 
significant by [CONTACT_093] , the investigator may use their site machine  to repeat the 
assessment. If both the site and vendor machines return an abnormal ECG finding, then the  
investigator should follow the guidance provided in section 6.[ADDRESS_421764] of clinical safety laboratory tests to be performed and the SoA 
(Section  1.3) for the timing and frequency. All protocol -required laboratory assessments, as 
defined in Appendix 2,  must be conducted in accordance with the Laboratory Manual and the 
SoA (Section  1.3). The SoA also includes information on allowable windows for testing and 
windows for screening tests to be used for C1D1. Unscheduled clinical laboratory 
measurements may be obtained at any time during the study to assess any perceived safety 
issues.  
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. 
Clinically significant abnormal laboratory findings are those which are not associa ted with 
the underlying disease, unless judged by [CONTACT_78259]'s condition.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421765] dose of study intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by [CONTACT_10982].  
If such values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_093], the etiology should be identified and the sponsor notified.  
See Appendix 6 for suggested actions and follow -up assessments in the event of a potential 
DILI.  
No need to repeat clinical laboratory assessments on C1D1 if the baseline assessment was performed within 96 hours prior to that date.  
For participant convenience, the blood tests performed during any non- clinic visit (except PK 
or biomarker collections) day may be performed at the study center or locally (ie, licensed 
laboratory) and the lab results sent to the Principal Investigator.  
If laboratory values from non- protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by [CONTACT_737] (eg, SAE, AE, or dose modification), then the results 
must be recorded in the eCRF.  
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting  
The definitions of an AE and an SAE can be found in Appendix 3 . 
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant's legally 
authorized representative), or they may arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (Section 7.2).  
During the active collection period as described in Section 8.3.1 , each participant  will be 
questioned about the occurrence of AEs in a nonleading manner.  
In addition, the investigator may be requested by [CONTACT_22835] -up 
information in an expedited fashion.  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study (ie, before undergoing 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 60 
 any study related procedure and/or receiving study intervention), through and including a 
minimum of [ADDRESS_421766] administratio n of the study intervention  (ie, study 
drug treatment or surgical resection, whichever occurs last).  
Follow- up by [CONTACT_340757] a level acceptable to the 
investigator. 
When a clinically important AE remains ongoing at the end of the active collection period, 
follow- up by [CONTACT_227985] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.  
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.  
If the participant withdraws from the study and also withdraws consent for the collection of future information, the active collection period ends when consent is withdrawn.  
If a participant  permanently discontinues or temporarily discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SA E 
reported using the SAE Report Form.  
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has completed the study, and he/she 
considers the event to be reasonably related to the study intervention, the investigator must 
promptly report the SAE to [COMPANY_007] using the SAE Report Form.  
[IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety  
All SAEs occurring in a participant during the active collection period as described in 
Sections  8.3.[ADDRESS_421767] still be reported to [COMPANY_007] Safety irrespective of any intervening treatment. Note that a switch to a commercially available version of the study intervention is 
considered as a new anticancer therapy for purposes of  SAE reporting.  
[IP_ADDRESS].  Recording Nonserious AEs and SAEs on the CRF  
All AEs and SAEs occurring in a participant during the active collection period which begins  
after obtaining informed consent , as described in Section  8.3.[ADDRESS_421768] administration of study intervention . Participants who undergo surgical resection 
>[ADDRESS_421769] 
dose of study drug.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421770] to the CRF requirements as described in Section  5.4. 
If a participant begins a new anticancer therapy, the recording period for nonserious AEs 
ends at the time the new treatment is started; however, SAEs must continue to be recorded on 
the SAE CRF  during the above -indicated active collection period. Note that a switch to a 
commercially available version of the study intervention is considered as a new anticancer 
therapy for the purposes of SAE reporting.  
8.3.2.  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open and 
nonleading verbal  questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.3.3.  Follow- Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant  is lost to follow -up (Section  7.4). 
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of possible causality. Any infor mation relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety.  
Further information on follow- up procedures is given in Appendix [ADDRESS_421771] the saf ety of participants and the safety of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country- specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs , and investigators.  
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to loc al regulatory 
requirements and sponsor policy and forwarded to investigators , as necessary.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 62 
 An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with t he SRSD(s) and 
will notify the IRB/EC, if appropriate according to local requirements.  
8.3.5.  Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure  
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, family members, and others who may be exposed. An 
environmental exposure may include EDP, EDB, and occupational exposure.  
Any such exposure to the study intervention under study are reportable to the sponsor within 24 hours of investigator awareness.  
[IP_ADDRESS].  Exposure During Pregnancy  
An EDP occurs  if:  
• A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure. Below are examples of 
environmental EDP:  
o A female family member or healthcare provider reports that she is pre gnant after 
having been exposed to the study intervention by [CONTACT_22837].  
o A male family member or healthcare provider who has been exposed to the 
study intervention by [CONTACT_78262], or skin contact [CONTACT_340758].  
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery ( see below for information related to 
termination of pregnancy).  
• If EDP occurs in a participant’s partner, the investigator must report this information 
to [COMPANY_007] Safety on the SAE Report Form and an EDP Supplemental Form, regardless 
of whether an SAE has occurred.  Details of the pregnancy will be collected after the 
start of study intervention and until [ADDRESS_421772] ARV -471 or anastrozole 
dose. 
• If EDP occurs in the setting of environmental exposure, the investigator must report information to [COMPANY_007] Safety using the SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study,  the information is not recorded on a CRF; however, a copy of the 
completed SAE Report Form is maintained in the investigator site file.  
Follow- up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 63 
 follow- up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are reported). 
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional  information about pregnancy outcomes that are reported to 
[COMPANY_007] Safety as SAEs follows:  
• Spontaneous abortion including miscarriage and missed abortion;  
• Neonatal deaths that occur within [ADDRESS_421773] 
to causality, a s SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow- up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver  to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his partner.  
[IP_ADDRESS].  Exposure During Breastfeeding  
An EDB occurs  if:  
• A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental EDB is a female family member or healthcare provider who reports that she is 
breastfeeding after having been exposed to the study intervention by [CONTACT_22837].  
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information  must be reported 
using the SAE Report Form. When EDB occurs in the setting of environmental exposure, the 
exposure information does not pertain to the participant enrolled in the study, so the 
information is not recorded on a CRF. However, a copy of the completed SAE Report Form 
is maintained in the investigator site file.  
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 64 
 if the infant experiences an SAE associated with such a drug, the SAE is reported together 
with the EDB.  
[IP_ADDRESS].  Occupational Exposure  
The investigator must report any instance of occupational exposure to [COMPANY_007] Safety within 
24 hours of the investigator’s awareness using the SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed SAE Report Form must be maintained in the investigator 
site file.  
8.3.6.  Lack of Efficacy  
The investigator must report signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy. Lack of efficacy or failure of expected pharmacological action is reportab le to the 
sponsor only if associated with an SAE .  
8.3.7.  Medication Errors  
Medication errors may result from the administration or consumption of the study 
intervention by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.  
Medication errors are recorded and reported as follows:  
Recorded  on the 
Medication Error page 
of the CRF Recorded on the  
Adverse  Event page  
of the CRF  Reported on the CT SAE 
Report  Form to [COMPANY_007] Safety 
Within 24 Hours of 
Awareness  
All (regardless of 
whether associated with 
an AE)  Any AE or SAE associated 
with the medication error  Only if associated with an SAE  
Medication errors include:  
• Medication errors involving participant exposure to the study intervention;  
• Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the study participant.  
Such medication errors occurring to a study partici pant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.  
In the event of a medication dosing error, the sponsor should be notified within 24 hours.  
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.   
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 65 
 Medication errors should be reported to [COMPANY_007] Safety within 24  hours on a SAE Report Form 
only when associated with an SAE.  
8.4. Pharmacokinetics  
For participants receiving ARV -471 only (Arm A), blood sampling for PK analysis will be 
conducted as specified in Table 3. 
8.4.1.  Collection of Samples  
For participants receiving ARV -471, venous blood samples will be collected for PK. At visits 
during which blood samples for the determination of multiple as pects of study treatment will 
be taken, one sample of sufficient volume can be used. Additional samples may be collected 
at additional time points during the study if agreed upon between the Investigator and the 
Sponsor (eg, insufficient sample volume to complete testing or to help assess or follow up on any suspected drug- related AE). 
The actual date and time (24 -hour clock time) of each PK sample will be collected and 
recorded in the eCRF. The actual dose amount, date, and time of the previous ARV -[ADDRESS_421774] one subsequent dose in each PK sample collection day will be recorded. PK 
samples will be collected, processed, labeled, stored, and shipped as detailed in the study 
Laboratory Manual.  
[IP_ADDRESS].  Determination of Drug Concentration  
PK samples for the determination of ARV -471 and ARV -473 in plasma will be analyzed 
using a validated bioanalytical method measuring both ARV -471 and ARV -473 using a 
chiral assay. Full details of the bioanalytical methods will be described in separate 
Bioanalytical Reports. All PK samples within the known stability window at the time of 
receipt by [CONTACT_115009]. Plasma samples may be subjected to 
further analysis by [CONTACT_340759]/or to investigate the presence of ARV -471 and/or its metabolites. 
Samples collected for analyses of concentrations of ARV -471 and ARV -473 may also be 
used to evaluate safety or efficacy aspects related to concerns arising during or after t he 
study. 
[IP_ADDRESS].  Determination of Pharmacokinetic of Individual Participants  
Plasma concentrations of ARV -471 and ARV -473 from sparse PK sampling will be analyzed 
using population PK approach to determine exposure and clearance parameter values for 
individuals. T he effects of concomitant medications, participant demographics (eg , race, age, 
body size), and intrinsic factors such as renal or hepatic functions on ARV -471 and ARV -
473 will be explored. A separate population PK report may be issued following the 
comple tion of the study.  
8.5. Genetics  
8.5.1.  Specified Genetics  
Genetics (specified analyses) are not evaluated in this study.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421775] cancer or 
drug response may also be performed including, but not limited to, PgR expression,  
 
 
 
Samples may be stored for a maximum of 10 years (or according to local regulations) 
following the last participant’s last visit for the study at a facility selected by [CONTACT_340760].  
8.6.1.  Mandatory Tumor Biopsies  
Tumor samples for PD endpoints and other biomarker research that should be collected from 
participants are:  
• Screening: [ADDRESS_421776] tumor  
• On-treatment biopsy on C1D15 (+ 5 days): [ADDRESS_421777] tumor  
• Tumor samples from surgical resection (after approximately 5.5 months of 
treatment): equivalent of  3 to 5 core biopsies, at minimum 
Details on biopsy collection and processing are provided in the Laboratory Manual.  
9. STATISTICAL CONSIDERATIONS  
Detailed methodology for summary and statistical analyses of the data collected in this study 
is ou tlined here and further detailed in the SAP, which will be maintained by [CONTACT_456]. 
The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be  reflected in a 
protocol amendment.  
9.1. Statistical Hypotheses  
9.1.1.  Multiplicity Adjustment  
This is a Phase 2 POC study designed to generate data informing future studies about 
ARV -471. There are no plans for formal comparisons or hypotheses testing. There is no ne ed 
for Type I error control.  

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 67 
 9.1.2.  Estimands  
[IP_ADDRESS].  Primary Estimands  
The primary estimand of this study is defined as the percent change in Ki -67 expression 
between baseline and C1D15 tumor biopsies observed from each Arm, respectively. 
Descriptive statistics will be provided to evaluate the effects of ARV -471 and anastrozole , 
respectively,  on Ki -67 expression in tumors after two weeks of treatment. No comparisons 
between the treatment arms are planned.  
Treatments:  ARV -471 (Arm A) and anastrozole (Arm B)  
Population:  post-menopausal women with newly diagnosed and treatment naive 
ER+/HER2 – breast cancer that is amenable to definitive surgical resection. Participants must 
also have tumor that is at least 1.[ADDRESS_421778] one dose of study treatment and had evaluable Ki -67 
measurements from baseline and C1D15 visits.  
Variable:  the log- transformed Ki -67 after approxim ately two weeks of treatment as a 
percentage of the baseline value, ie, the ratio between the Ki -67 measurements obtained from 
C1D15 visit and baseline.  
Intercurrent events:  only participants with evaluable Ki -67 results from baseline and 
C1D15 visits will be included in the primary analysis. No participants will be censored or 
excluded due to any reasons other than missing Ki -67 data.  
Population- level summary:  the log- transformed percentage Ki -67 will be modelled using a 
GLM. Refer to Section  9.3.2  and the SAP for more details.  
[IP_ADDRESS].  Secondary Estimands  
There are no key secondary endpoints defined for this study. No estimands are defined for 
any of the secondary or exploratory endpoints. Statistical analyses for the secondary and exploratory endpoints are described in Section  9.[ADDRESS_421779] one dose of study treatment and had evaluable Ki -67 
measurements from baseline and C1D15 visits.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 68 
 Participant Analysis Set  Description  
Pharmacodynamic /Biomarker 
Analysis Set(s)  The Pharmacodynamic  /Biomarker analysis population is defined 
as all enrolled  participants with a t least 1 of the Pharmacodynamic 
/Biomarkers evaluated at pre and/or post dose.  
Pharmacokinetic  Analysis 
set(s)  PK Concentration Analysis Set  
The PK Concentration Analysis Set includes all participants in the 
Safety  Analysis Set who have at least one plasma concentration 
(including those below the limit of quantification) for ARV -471, 
or ARV -473. 
PK Parameter Analysis Set  
The PK Parameter Analys is Set will include all participants in the 
Safety Analysis Set who have at least one PK parameter of interest 
for ARV -471, or ARV- 473 (C max or AUC).  
PK Pre -Dose Concentration (C trough) Analysis Set  
The PK Pre -Dose Concentration Analysis Set will include all 
participants in  the Safety  Analysis Set who have at least one 
evaluable C trough and within the allowable time window following 
treatment for ARV -[ADDRESS_421780]:  
• Dosing time from the day prior to PK sample collection is 
known. 
The allowable time window is the period of time between 
22 hours after dosing on the day prior to  the sample 
collection,  and 30 minutes after dosing on the day of 
sample collection.  
• Dosing time from the day prior is not available.   
The allowable time window is the period of time between 2 hours 
before dosing and 30 minutes  after dosing on the day of sample 
collection . 
9.3. Statistical Analyses  
The SAP will be developed and finalized before any a nalyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analyses of the primary and secondary endpoints. 
9.3.1.  General Considerations  
No formal comparisons between ARV -471 and anastrozole or hypotheses testing are planned 
for this study . Descriptive  statistics (including point estimates and two -sided CIs) will be 
provided for all parameters of interest. For information purposes, all the 2-sided CIs will be 
reported on both 80% and 95% confidence levels.  
Statistical analyses for the primary and secondary endpoints are summarized below and in 
the SAP.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 69 
 9.3.2.  Primary Safety/Efficacy Analyses   
Ki-67 expression will be asses sed by [CONTACT_340732] a central laboratory.  
Analysis of Ki -67 reduction will be based on a Ki -67 evaluable population. The 
log-transformed Ki -67 after approximately 2 weeks of treatment as a percentage of the 
baseline value, ie, the ratio between the Ki -67 measurements obtained from C1D15 visit and 
baseline, will be modelled using a GLM, with both stratification factors ( ie, baseline Ki -67 
score and the tumor size) and treatment as covariates. Treatment effects for each arm will b e 
summarized using the LSM and their two-sided CIs on the log scale. In addition, for easier 
interpretation of the data, the treatment effects will be back transformed and expressed as the 
geometric means and their CIs on the original percentage scale by t reatment arm. The percent 
change, in other words, relative reduction, of Ki -67 after 2 weeks of treatment will also be 
reported as the complement of the ratio between the Ki -67 measurement from C1D15 and 
baseline, ie, 100% × (1-Ki-67 from C1D15/Ki -67 from baseline) . Similar modeling will be 
applied to ER data .  
9.3.3.  Secondary Endpoint(s)/Estimands Analysis  
pCR is defined as no invasive cancer in the breast and sampled axillary lymph nodes 
following completion of neoadjuvant systemic therapy. The rate of pCR will be reported for each arm using both point estimates and exact Wilson  CIs. Odds ratios between the 
treatments will also be reported using mPEPI [INVESTIGATOR_340719] a 
numerical score following NET , including Ki67 expression in the surgical specimen, 
pathologic tumor size, and lymph node status. The proportion of participants achieving 
mPEPI  [INVESTIGATOR_32005] 0 after treatment will be evaluated.  
To support secondary objective of evaluating clinical and pathologic response, binary or 
categorical endpoint such as pathologic stage, pCR, and participants with mPEPI [INVESTIGATOR_340720] (C6D18 ± 14 days), rates of BCS , radiographic response  per 
mRECIST  in the primary tumor during Cycle [ADDRESS_421781] CI using Wilson  method; For 
caliper -based response on C6D1, best percentage change from baseline will be graphed by 
[CONTACT_2939]. All clinical and pathologic response will be listed for randomized participants 
by [CONTACT_2939].  
9.3.4.  Tertiary/Exploratory Endpoint(s)  
CCCA at Week 2 is defined as Ki67 score ≤2.7%.  An estimate of the difference in the 
observed CCCA rates and corresponding 80% as well as 95% CIs will be calculated . Odds 
ratios between the treatment s adjusted for the stratification factors  through the 
Cochran -Mantel-Haenszel  method will be provided along with the ir CIs.  
9.3.5.  Subgroup Analyses  
Summar ies of the primary endpoint will be presented  for subgroups defined by [CONTACT_54041]:  
• Size of primary breast tumor (T -stage) : ≤2 cm, > 2 to <5 cm , or ≥5 cm  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 70 
 • Baseline Ki-67 score (assessed local ly): <20% vs ≥20% 
Other factors will be considered if the observed data  imply potential findings of clinical 
interest . Results of the primary analysis will be reported within each subgroup. Forest plots 
will be provided.  
9.3.6.  Other Safety Analyses  
All safety analyses will be performed on the safety population. Descriptive statistics of safety 
will be presented using NCI CTCAE v5.0. All TEAEs, drug -related AEs, SAEs and 
drug- related SAEs will be tabulated using worst grade per NCI CTCAE v5.[ADDRESS_421782] 
grade per NCI CTCAE v5.0 criteria. The extent of exposure including number of doses , 
duration of treatment, and dose modifications will be summarized by [CONTACT_2939]. A 
summary of deaths with reasons will be provided for all treated participants.  
AEs, ECGs, BP, pulse rate, cardiac monitoring results, and safety laboratory data will be 
reviewed and summarized on an ongoing basis during the study to evaluate the safety of 
participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.  
Medical history and physical examination and neurological examination information, as 
applicable, collected during the study will be considered source data and will not be required to be  reported, unless otherwise noted. However, any untoward findings identified on 
physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at 
screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless 
otherwise noted. Demographic data collected at screening will be reported. 
9.4. Sample Size Determination  
There are no plans for formal comparisons between ARV -471 and anastrozole. No power 
calculations are needed. Approximately 150 participants will be randomized to the two 
treatment arms in 2:1 ratio (100 participants to the  ARV -471 arm and 50 participants to the 
anastrozole arm). These numbers were chosen to provide meaningful information about the 
primary endpoint, ie, changes (on- treatment C1D15 vs baseline) in Ki -[ADDRESS_421783] of probable scenarios demonstrating the width of the CIs 
for the primary endpoint under the assumption that 80% (ie, n= 120) of the randomized 
participants will provide valid Ki- 67 measurements from both their baseline and C1D15 
visits.  Table 7 indicates that the width of the 80% CIs of the mean percentage Ki -67 after 
2 weeks  of treatment by [CONTACT_340728] -471 will not exceed 14% and the width of the 95% CIs will 
not exceed 21.6% if the mean percentage of the corresponding baseline values after 2 weeks 
of treatment ranges from approximately 20% to 40%. The planned sample size will provide 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421784] in terms of the reduction of Ki- 67 with reasonable 
precision. 
Table 7 Confidence Intervals for Mean Percentage of Baseline Value in Ki- 67 After 
Two Weeks  
Number of 
participants/ arma  Mean 
percentage  
Ki-67 in two 
weeks b SD of log - 
transformed 
percent change in 
Ki-67c 80% CI d 95% CI d 
100 (80 evaluable)  
 20% 
1.0 (17.3%, 23.1%)  (16.0%, 25.0%)  
30% (26.0%, 34.7%)  (24.0%, 37.5%)  
40% (34.6%, 46.2%)  (32.0%, 50.0%)  
20% 
1.2 (16.8%, 23.8%)  (15.3%, 26.1%)  
30% (25.2%, 35.7%)  (23.0%, 39.2%)  
40% (33.6%, 47.6%)  (30.6%, 52.2%)  
50 (40 evaluable)  
 20% 
1.0 (16.3%, 24.6%)  (14.5%, 27.5%)  
30% (24.4%, 36.9%)  (21.8%, 41.3%)  
40% (32.5%, 49.2%)  (29.1%, 55.1%)  
20% 
1.2 (15.6%, 25.6%)  (13.6%, 29.4%)  
30% (23.4%, 38.4%)  (20.4%, 44.0%)  
40% (31.2%, 51.2%)  (27.3% 58.7%)  
a. Approximately [ADDRESS_421785] normal distribution on the log scale. Various values for the SD of the log -transformed Ki -67 percent 
change are provided to mimic the variability reported in the coopERA study (Hurvitz 202 2a). 
d. The CIs are presented in the original percentage scale through exponential -transformation of the Cis generated using 
the log -transformed Ki -67 data.  
 
Table 8 Confidence Intervals for the Ratio Between the Mean Percentage of Baseline 
Values  for Ki-67 Observed from ARV -471 and Anastrozole Arms (Ki -67 
Evaluable Participants N=120)  
Mean 
percentage 
Ki-67 with 
ARV -471a  Mean 
percentage 
Ki-67 with 
anastrozolea  SD of log- 
transformed 
percentage 
Ki-67b Difference of 
mean 
percentage 
Ki-67 
(anastrozole 
– ARV -471) 80% CI for the 
ratio of mean 
percentage Ki -67c 95% CI for the 
ratio of mean 
percentage 
Ki-67c 
20% 30% 1.0 
10% (1.17, 1.93)  (1.02, 2.20)  
30% 40% (1.71, 1.04)  (0.91, 1.96)  
20% 30% 1.2 (1.11, 2.02)  (0.95, 2.38)  
30% 40% (0.99, 1.80)  (0.84, 2 .11) 
20% 28% 1.0 
8% (1.09, 1.80)  (0.95, 2.05)  
30% 38% (0.99, 1.63)  (0.86, 1.86)  
20% 28% 1.2 (1.04, 1.89)  (0.88, 2.22)  
30% 38% (0.94, 1.71)  (0.80, 2.01)  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 72 
 20% 25% 1.0 
5% (0.97, 1.60)  (0.85, 1.83)  
30% 35% (0.91, 1.50)  (0.80, 1.71)  
20% 25% 1.2 (0.93, 1.69)  (0.79, 1.98)  
30% 35% (0.86, 1.57)  (0.74, 1.85)  
a. Assume the relative reduction in Ki -67 attributed to ARV -471 exceeds the reduction attributed to anastrozole by 
5%, 8% and 10% respectively in various scenarios. 
b. Assume the same SD for the log - transformed percent change in Ki -67 in either arm.  
c. The ratio is defined as the mean percentage Ki -67 with anastrozole divided by [CONTACT_340761] -67 with 
ARV -471. A ratio above unity (1) is in favor of ARV -471. 
 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 73 
 10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines; 
• Applicable ICH GCP guidelines;  
• Applicable laws and regulations, including applicable privacy la ws. 
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_456], submitted to an IRB/EC 
by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is ini tiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study participants.  
The investigator will be responsible for the following:  
• Providing written summaries of the status o f the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC.  
• Notifying the IRB/EC of SAEs or other significant safety findings as required by [CONTACT_1744]/EC procedures.  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21  CFR, ICH GCP guidelines, the IRB/EC, applicable European 
regulations, and all other applicable local regulations.  
• After reading the protocol, each Investigator will sign the  protocol signature [CONTACT_25327] a copy of the signed page to the Sponsor or representative. The study will not 
start at any study center at which the Investigator has not signed the protocol.  
[IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the Protoco l or ICH GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_340762], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, the sponsor should be informed immediately.  
In addition, the investigator will inform the sponsor immediately of any urgent safety 
measures taken by [CONTACT_340763]-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421786], and of any serious breaches of this protocol or of the ICH GCP that the investigator 
becomes aware of.  
10.1.2.  Financial Disclosure  
Investigators and sub- Investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification  or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing updated information on financial interests during 
the course o f the study and for one year after completion of the study.  
10.1.3.  Informed Consent Process  
The investigator or his/her representative will explain the nature of the study, including the risks and benefits, to the participant or her legally authorized representat ive and answer all 
questions regarding the study. The participant or her legally authorized representative should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary. Participants or their 
legally authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, ICH GCP guidelines, privacy and data protection requirements, where applicable, and the IRB/EC or study center.  
The investigator must ensure that each study participant or her legally authorized 
representative is fully informed about the nature and objectives of the study, the sharing of 
data r elated to the study, and possible risks associated with participation, including the risks 
associated with the processing of the participant’s personal data.  
The participant or her legally authorized representative must be informed that his/her 
personal s tudy- related data will be used by [CONTACT_78271]. The level of disclosure must also be explained to the participant or her legally 
authorized representative.  
The participant or her legally authorized representative must be informed that his/her medical 
records may be examined by [CONTACT_340764], by [CONTACT_6667]/EC members, and by [CONTACT_6668].  
The investigator fur ther must ensure that each study participant or her legally authorized 
representative is fully informed about his or her right to access and correct his or her personal 
data and to withdraw consent for the processing of his or her personal data.  
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was obtained. The authorized person obtaining the informed consent must also sign the IC D. 
Participants or her legally authorized representative must be reconsented to the most current version of the ICD(s) during their participation in the study.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 75 
 A copy of the ICD(s) must be provided to the participant or the participant’s legally 
authorized  representative.  
A participant who is rescreened is not required to sign another ICD if the rescreening occurs within [ADDRESS_421787] party, unless required to do so by [CONTACT_2371].  
Extra precautions are taken to preserve confidentiality and prevent genetic data being linked 
to the identity of the participant. In exceptional circumstances, however, certain individuals 
might see both the genetic data and the personal identifiers of a participant. For example, in 
the case of a medical emergency, the Sponsor or representative physician or an Investigator 
might know a participant’s identity and also have access to his or her genetic data. Also, 
regulatory authorities may require access to the relevant files.  
All parties will comply with all applicable laws, including laws regarding the implementation of organizational and technical measures to ensure protection of participant data.  
Participants’ personal data will be stored at the study site securely to ensure that only 
authorized  study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to th e 
sponsor will be identified by [CONTACT_20007], participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study agreement and applicable privacy laws.  
10.1.5.  Committees Structure  
Please refer to Section  4.4. 
10.1.6.  Dissemination of Clinical Study Data  
The results of the study should be reported within one year from the end of the clinical trial. 
Irrespective of the outcome, the Sp onsor will submit to the appropriate database a summary 
of the results  of the clinical trial within one year from the end of the clinical trial. It shall be 
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 76 
 accompanied by a summary written in a manner that is understandable to laypersons (where 
applicable).  
10.1.7.  Data Quality Assurance  
All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data e ntries are accurate and correct by [CONTACT_18027].  
The investigator must ensure that the CRFs are securely stored at the study site to prevent 
access by [CONTACT_20011].  
The investigator must permit study- related mo nitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification may also occur after study completion. It is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy, including the definition of study critical data items 
and processes (eg, risk -based initiatives in operations and quality, such as risk management 
and mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on-s ite monitoring), are provided in the Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study, including quality checking of the data.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_421788] ensure that the records continue to be stored securely for as long as they are maintained.  
When participant data are to be d eleted, the investigator will ensure that all copi[INVESTIGATOR_306891].  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the stud y. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and in vestigator will promptly resolve any discrepancies that are identified 
between the study data and the participant ’s medical records. The investigator will promptly 
provide copi[INVESTIGATOR_19946]. Before response 
submi ssion to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421789] maintain accurate documentation (source data) that supports t he 
information entered in the CRF. Source data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail).  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, the ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
The study s tart date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the date of the first participant’s first visit and will be the study 
start date.  
Criteria for Stoppi[INVESTIGATOR_340721]. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study- site closure visit has been performed.  
The investigator may initiate study -site closure at any time upon notification to the sponsor 
or designee if requested to do so by [CONTACT_22846]/EC or if s uch termination is required 
to protect the health of study participants.  
Reasons for the early closure of a study site by [CONTACT_19711]: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/E C or local health authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines; 
• Inadequate recruitment of participants by [CONTACT_093];  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 78 
 • Discontinuation of further study intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the E cs/IRBs, the regulatory authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study termination is also provided for in the clinical study agreement. If there is any conflict between the contract and this protocol, the contract will contr ol as to termination rights.  
10.1.10.  Publication Policy  
If publication is addressed in the clinical study agreement, the publication policy set out in 
this section will not apply.  
The data generated by [CONTACT_115027]. The publication 
policy with respect to the Investigator and study center will be set forth in the Clinical Trial 
Agreement.  
The results of this study may be published or presented at scientific meetings. The Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.  
The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual study center 
data. In this case, a Coordinating Investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_340765] s authorship requirements.  
10.1.11.  Sponsor’s Qualified Medical Personnel  
The contact [CONTACT_1133] ’s appropriately qualified medical personnel for the 
study is documented in the  study contact [CONTACT_4111].  
To facilitate access to appropriately qualified medical personnel for study related medical questions or problems, participants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, 
(b) participant’s study identification number, (c) site emergency phone number active 
24 hours/day, 7 days per week, and (d) the sponsor Call Center number.  
The ECC is intended to augment, not replace, the established communication pathways 
between the investigator, site staff, and study team. T he ECC is to be used by [CONTACT_340766], as a means of reaching the investigator or site staff related to the care of a participant. The sponsor Call Center number should only 
be used when the investigator and site staff cannot be reached. The sponsor Call Center 
number is not intended for use by [CONTACT_240875]; if a participant calls that number 
directly, he or she will be directed back to the investigator site.  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 84 
 terminology and the same AE term should be used on both the CRF and the SAE Report 
Form for reporting of SAE information.  
Safety Event  Recorded on the CRF  Reported on  the SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness  
SAE  All All 
Nonserious AE  All None  
Exposure to the study 
intervention under study 
during pregnancy or 
breastfeeding  All A Es/SAEs associated 
with EDP or breastfeeding 
 
Note:  Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.  All instances of EDP are 
report ed (whether or not 
there is an associated 
SAE)*  
All instances of EDB are reported (whether or not there is an associated 
SAE). **  
Environmental or 
occupational exposure 
to the product under 
study to a non-
participant (not 
involving EDP or EDB).  None. Exposure to a study 
non-participant is not 
collected on the CRF.  The exposure (whether or 
not there is an associated AE or SAE) must be 
reported.*** 
* EDP  (with or without an associated AE or SAE): any pregnancy information is reported to the 
sponsor using SAE Report Form and EDP Supplemental Form; if the EDP is associated with an SAE, 
then the SAE is reported to the sponsor using the SAE Report Form.  
**  EDB  is reported to the sponsor using the SAE Report Form which would also include details of 
any SAE that might be associated with the EDB.  
*** Environmental or Occupational exposure:  AEs or SAEs associated with occupational 
exposure are reported to the s ponsor using the SAE Report Form.  
• When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.  
• The investigator will then  record all relevant AE or SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the sponsor in lieu of completion of the SAE Report Form/AE or SAE CRF page.  
• There may be instances  when copi[INVESTIGATOR_215825]. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_340722].  
ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 87 
 RUSSIAN 
FEDERATION: 
Armenia, Azerbaijan, 
Belarus, Georgia, 
Kazakhstan, 
Kyrgyzstan, Mongolia, 
Tajikistan, 
Turkmenistan, 
Uzbekistan  GEORGIA  
SPAIN: Andorra  SPAIN  
UNITED STATES: 
American Samoa, 
Guam, Northern 
Mariana Islands, 
Puerto Rico, United 
States Virgin Islands 
and [LOCATION_002] 
Minor Outlying Islands  UNITED 
STATES  
Detailed instructions regarding the SAE submission process are to be found in the 
Investigator folder provided to each site.  
The Investigator, or designated party, should notify the appropriate IRB/EC of SAEs 
occurring at the study site and other AE reports received from the Sponsor, in 
accordance with local procedures and statutes.  
The Investigator, or designated party, should notify the appropriate IRB/EC of SAEs 
occurring at the study site and other AE reports received from the Sponsor, in 
accordance with local procedures and statutes.  
 
 

ARV-471 (PF-07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 88 
 10.4. Appendix 4: Contraceptive and Barrier Guidance  
All participants enrolled  in this study will be post -menopausal females as defined in 
Section  5.1, and thus contraceptive and barrier guidance does not apply.
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 89 
 10.5. Appendix 5: Genetics  
Not applicable  to this study. 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 90 
 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments  
Potential Cases of Drug Induced liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators, ” while those who show transient liver injury but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3  × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.” 
In the majority of  DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2 × ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_161651]/ALT 
is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be elevated within the 
same laboratory sample). In rare instances, by [CONTACT_29623] T bili elevations are detected, 
AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST or ALT in addition to T bili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.  
The threshold of  laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST or ALT values >3 × ULN AND a T bili value >2  × ULN with 
no evi dence of hemolysis and an alkaline phosphatase value <2 × ULN or not available.  
For participants with baseline AST or ALT or Tbili values above the ULN, the following 
threshold values are used in the definition mentioned above, as needed, depending on whic h 
values are above the ULN at baseline:  
Preexisting AST or ALT baseline values above the normal range:  AST or ALT values 
>2 times the baseline values AND >3 × ULN; or >8  × ULN (whichever is smaller).  
Preexisting values of T bili above the normal range: T bili level increased from baseline value 
by [CONTACT_8895] 1 × ULN or if the value reaches >3  × ULN (whichever is smaller).  
Rises in AST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any ca se where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 91 
 include laboratory tests, detailed history, and physical assessment. The possibility of hepatic 
neoplasia (primary or secondary) should be considered.   
In addition to repeating measurements of AST and ALT and Tbili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, creatine kinase, direct and indirect 
bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous analyses at the time of the recognized 
initial abnormalities to determine etiology. A detailed history, including relevant information, 
such as  review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family history, sexual history, travel history, history of contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis  A, B, C, D, and E infection, liver imaging (eg, biliary tract), and collection of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
Tbili elevation defined abo ve should be considered potential DILI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.   
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of reasonable investigations have been received and have excluded an alternative etiology.  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 93 
 • At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.  
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and sponsor, and not to be considered as 
all-inclusive of what to be reported as A Es/SAEs.  
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 94 
 10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI  
Participant s should not receive the following while participating in trials with ARV -471 
(unless utilized with caution to treat a drug- related AE when no alternative is available).  
Note: These lists are examples and are not intended to be exhaustive.  
• Examples of sensitive P -gp substrates and P -gp substrates with narrow therapeutic 
indices:  
P-gp substrates  with 
narrow therapeutic 
indices:  dabigatran etexilate, digoxin, fexofenadine, api[INVESTIGATOR_3822], rivaroxaban  
• Examples  of strong CYP3A4 inhibitors and inducers  
Strong CYP3A4 
inhibitors:  boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and 
ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, 
ketoconazole, lopi[INVESTIGATOR_14475], paritaprevir  and ritonavir 
and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, 
saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, 
telithromycin, troleandomycin, voriconazole clarithromycin, 
idelalisib, nefazodone, nelfinavir  
Strong CYP3A 
inducers:  apalutamide, carbamazepi[INVESTIGATOR_050], enzalutamide, mitotane, phenytoin, 
rifampin, St. John’s wort  
• Examples of known QT prolonging drugs:  
Known QT prolonging 
drugs:  aclarubicin, amiodarone, anagrelide, arsenic trioxide, astemizole, 
azithro mycin, bepridil, cesium chloride, chloroquine, 
chlorpromazine, chlorprothixene, cilostazol, ciprofloxacin, 
cisapride, citalopram, clarithromycin, cocaine, disopyramide, 
dofetilide, domperidone, donepezil, dronedarone, droperidol, 
erythromycin, escitalopram , flecainide, fluconazole, gatifloxacin, 
grepafloxacin, halofantrine, haloperidol, hydroquinidine, 
hydroxychloroquine, ibogaine, ibutilide, levolfoxacin, 
levomepromazine (methotrimeprazine, levomethdyl acetate, 
levosulpi[INVESTIGATOR_14956], meglumine antimoniate, mesorid azine, methadone, 
moxifloxacin, nifekalant, ondansetron, oxaliplatin, papaverine 
HCl (Intracoronary), pentamidine, pi[INVESTIGATOR_3924], probucol, 
procainamide, propofol, quinidine, roxithromycin, sertindole, 
sevoflurane, sotalol, sparfloxacin, sulpi[INVESTIGATOR_14956], sultopride, 
terfenadine, terlipressin, terodiline, thioridazine, vandetanib  
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 95 
 References:   
Examples of sensitive P -gp substrates and those with narrow therapeutic indices  
• https://www.fda.gov/drugs/drug- interactions -labeling/drug-development- and-drug-
interactions -tablesubstrates -inhibitors- and-inducers   
o Table 5 -1: Examples of clinical substrates for transporters (for use in clinical DDI 
studies and/or drug labeling) (12/03/ 2019)  
Examples of Strong CYP3A4 inhibitors (eg, itraconazole) and inducers (eg, rifampin)  
• https://drug -interactions.medicine.iu.edu/MainTable.aspx    
• https://www.fda.gov/drugs/drug- interactions -labeling/drug-development- and-drug-
interactions -tablesubstrates -inhibitors- and-inducers    
o Table 3 -2: Examples of clinical inhibitors f or P450 -mediated metabolisms (for 
concomitant use clinical DDI studies and/or drug labeling) (03/06/2020)   
o Table 3 -3: Examples of clinical inducers for P450- mediated metabolisms (for 
concomitant use clinical DDI studies and/or drug labeling) (12/03/2019)  
Examples of known QC prolonging drugs  
• https://www.crediblemeds.org/index.php   
  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 96 
 10.9. Appendix 9: Alternative Measures During Public Emergencies  
The alternative study measures described in this section  are to be  followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for  the duration of 
the COVID- 19 pandemic globally and will become effective for other public emer gencies 
only upon written notification from the sponsor.  
Use of these alternative study measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of any quarantines and travel bans/advisories).  
10.9.1.  Eligibility  
While SARS -CoV2 testing is not mandated for this study, local clinical practice standards for 
testing should be followed. A participant should be excluded if he/she has a positive test 
result for SARS -CoV2 infection, is known to have asymptomatic infection, or is suspected of 
having SARS -CoV2. Participants with active infections are excluded from study 
participation as per exclusion criteria, (Section  5.2). When the infection resolves, the 
participant may be considered for re -screening.  
10.9.2.  Telehealth Visits  
The use of Video TeleMed Visits during public emergencies will be acceptable in the 
following cases:  
Visits where only AE assessment and routine blood samples, which may be performed 
locally, are required and the results are received and reviewed by [CONTACT_340767].  
Visits occurring on Day [ADDRESS_421790] that prohibit travel or in- person clinic visits. In such cases, 
the Sponsor should be advised in advance, where possible, that a TeleMed visit will be used.  
The use of alternate or local labs and/or imaging centers is allowed at the discretion of the 
Investigator. Use of an alternate imaging center should have Sponsor approval prior to use.  
Study participants must be reminded to promptly  notify  site staff about any change in their 
health status.   
10.9.3.  Study Intervention  
Participants who cannot be seen in clinic due to quarantine requirements or other limitations 
due to public health emergencies may receive IP shipped, utilizing a secure delivery method 
with signature [CONTACT_60675], directly to their home address. The site is to confirm receipt of the 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421791] be 
provided in the participant’s medical record and their eCRF regarding all therapy received as 
well as all AEs related to COVID and its treatment.  
10.9.6.  Guidance for COVID vaccine administration  
[IP_ADDRESS].  For Participants Who Have Not Initiated Study Treatme nt  
It is recommended that they should receive the second dose of vaccine at least five days prior 
to initiation of study treatment. In addition, they should have completely recovered from any 
side effects related to administration of the vaccine before st arting study treatment.  
[IP_ADDRESS].  For Participants Already on Study Treatment and Beyond Cycle 1  
Participants who are already receiving study treatment and beyond Cycle  1, may receive the 
vaccine as it becomes available to them. Please carefully document any AEs that occur 
related to the vaccine administration and advise the Sponsor of any significant reactions that 
occur.  
 
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 98 
 10.10.  Appendix 10: Eastern Cooperative Oncology Group Performance Status  
Developed by [CONTACT_64850] (ECOG), Robert L. Comis, MD, 
Group Chair  
GRADE  ECOG PERFORMANCE STATUS  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, eg, light housework, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up an about more t han 50% of waking hours 
3 Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or chair  
5 Dead  
Oken M, Creech R, Tormey D. Toxicity  and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.  
1982;5:649-655. 
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 99 
 10.11.  Appendix 1 1: Radiological Imaging Assessment: modified RECIST 1.[ADDRESS_421792]/MRI body imaging  Contrast enhanced breast 
MRI  
Breast Ultrasound 
Breast Mammography  Study protocol is assessing 
treatment effect on breast 
cancer  primary tumor  
Measurable Disease  Non-nodal disease 
minimum size is [ADDRESS_421793] lesion 
minimum size is 1.5 cm ( 15 
mm) in the longest diameter  
Additional lesions  identified 
on breast imaging ( meeting 
RECIST 1.1  criteria ) may be 
identified and followed as 
target lesion s  Study protocol is assessing 
treatment effect on breast 
cancer primary tumor  and 
required imaging is  breast 
imaging 
Non-measurable 
Disease  Lesions can be 
identified from all 
organ groups  Lesions identified on breast 
imaging that do not meet 
target lesion criteria  Study protocol is assessing 
treatment effect on breast 
cancer primary tumor and 
required imaging is breast 
imaging  
Irradiated lesions  Previously irradiated 
lesions may be 
identified as a 
measurable lesion if the 
lesion demonstrates 
progressive disease  Exclusion criteria prohibits 
prior radiation treatment  Protocol exclusion criteria  
10.11.1.  Imaging Requirements  
Radiographic imaging (eg, breast ultrasound, breast MRI with contrast, and/or mammogram) 
is required during Screening, C4D1, and within [ADDRESS_421794] baseline imaging visits ( eg. C4D1, within [ADDRESS_421795] tumor).  A change in imaging technique (ie, modality) could result in lesion status 
being not evaluable.  
Breast imaging conducted as part of the participant’s routine clinical management (eg, 
ultrasound, MRI, mammogram) and obtained before signing of the ICD may be utilized for 
Screening or baseline purposes provided the procedures met the pr otocol- specified criteria 
and were performed within the time frame defined in the SoA (Section  1.3).  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421796] 1.5 cm (15 mm) in the 
longest diameter. Tumor imaging response assessment will be performed according to 
mRECIST 1.[ADDRESS_421797] 1.1 Disease Assessment  
[IP_ADDRESS].  Measurable Lesions at Baseline  
Measurable Lesions:  Lesions ide ntified on breast imaging that can be accurately measured in 
at least 1 dimension , are reproducible and represent study disease . 
• Primary breast lesion  with a minimum  measurement of 1.5 cm (15 mm)  in the longest 
diameter measurement  
• A non-nodal (not primary breast  tumor) lesion that can be accurately measured at 
baseline with a minimum measurement of [ADDRESS_421798] diameter 
measurement and is suitable for accurate repeated measurements.  
• A pathological (malignant) lymph node that can be accurately measured at baseline with a minimum measurement of 15 mm in the short axis measurement  are 
considered measurable and assessable as target lesions.  
• If imaging is breast MRI  and MRI  slice thickness  is more than 5 mm, the minimum 
size of measurable disease at baseline should be twice the slice thickness of the 
baseline scan. Up to 5 lesions per organ type (eg, breast tissue, lymph nodes , chest 
wall) may be recorded.  
• Soft tissue component of bone may be identified as target lesion if the soft tissue 
component measurement is at least 10 mm (the lesion must be in a location that will be included in the field of view on subsequent breast imaging).  
[IP_ADDRESS].  Nontarget Lesions at Baseline  
Non measurable disease i ncludes all other lesions , (or sites of disease)  identified on breast 
imaging not recorded as target lesion as well as non -nodal lesions that are too small to be 
considered measurable and truly non measurable lesions  that represent study disease , such a s 
pathological lymph nodes with short axis measurement between [ADDRESS_421799] 
wall disease and/or osseous bone lesions.  
Lesions identified on staging standard of care imaging may be entered as non -target lesion 
and followed for response assessment.  
[IP_ADDRESS].  Normal Sites of Disease  
Cystic lesions: Simple cysts should not be considered as malignant lesions and should not be 
recorded either as target or non -target disease. Cystic lesions thought to represent cystic 
metastases can be measurable lesions if they meet the specific definition above. If non- cystic 
lesions are also present, these are preferred as target lesions.  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 101 
 Normal nodes: lymph nodes with short axis <10 mm are considered normal and should not 
be recorded or followed either as measurable or as non -measurable disease.  
[IP_ADDRESS].  Recording Modified RECIST 1.1 Tumor Assessments 
All sites of disease should be assessed at baseline. Baseline assessments should be done as 
close as possible to the start of study treatment  and within 28  days prior randomization . If 
baseline assessment is inadequate or missing, subsequent statuses generally should be 
recorded as not evaluable until progressive disease is identified.  
Target Lesions  
Target lesions should be selected based on s ize (longest lesions) and suitability for accurate 
repeated measurements. The site and location of each target lesion will be recorded as well as 
the longest diameter for each non- nodal lesion and the shot axis diameter for each 
pathological lymph node tha t meet the size criteria for a target lesion. The SOD of the target 
lesions at baseline will be the basis for comparison to post baseline imaging assessments and the post baseline SOD.  
Target lesions will be assessed post baseline for lesion status and mea surements recorded. 
The SOD will be compared to baseline SOD and to nadir (smallest SOD on study) SOD to 
derive the target lesion response (see Table 11 ).  
Post-Baseline Target Lesion Special Considerations:  
• Actual measurements for target lesion (nodal and non- nodal) should continue to be 
recorded  (including nodes that have reduced to normal  size) .  
• Target lesions (nodal and non- nodal) that are too small to measure should be 
considered  as a default value of 5 mm.  
• Target lesions (nodal and non- nodal) that are considered to have disappeared should 
be recorded as 0 mm (including nodes that are no longer visible on imaging).  
• If a target lesion cannot be measured accurately due to it being too large, provide an estimate of the size of the lesion.  
• If a target lesion disappears (or reduces to normal size for lymph node) and reappears 
at a subsequent time point, the lesion should continue to be measured and included in the SOD. In the event that all target lesions achieved  CR status, the lesion 
reappearance would be considered as progressive disease at the time of reappearance.  
• If 2 or more target lesions coalesce (merge), the measurement of the coalesced mass 
is recorded and used in the SOD.  
• If a large target lesion splits into 2 or more parts, each part is recorded, and the sum of 
the parts is used in the SOD.  
• When a target lesion has had any intervention (ie, radiotherapy, embolization, 
surgery) during the study, the size of the target lesion should still be provided whe n 
possible. If the invention results in the target lesion measurement not possible, the 
target lesion should be identified as Not Evaluable.  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 102 
 • If one or more target lesion is Not Evaluable, and the sum of diameters meets the 
criteria for progressive disease,  progressive disease overrides not e valuable as the 
target lesion response.  
• Target lesion response of progressive disease requires 20% increase in the SOD of all 
target lesions AND a minimum absolute increase of [ADDRESS_421800] -baseline visit the NTL status (ie, Present, Absent, Not Evaluable, Not Assessed) 
will inform the NTL response. To achieve ‘unequivocal progression’ on the basis of 
non-target lesions, there must be an overall level of substantial worsening in non- target 
disease such that, even in presence of SD or PR in target lesions, the overall tumor burden 
has inc reased sufficiently to merit discontinuation of treatment. A modest ‘increase’ in the 
size of one or more non- target lesions is usually not sufficient to qualify for unequivocal 
progression status. See  Table [ADDRESS_421801] baseline visit, imaging will be assessed for any new lesions. Details of any new lesions will also be recorded with the date of assessment and lesion location/description. The 
presence of one or more new lesions is assessed as progressive disease. A lesion identified at a follow up assessment in an anatomical location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression.  
The finding of a new lesion should be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something other than tumor.  
If a new lesion is  equivocal, for example because of its small size, the treatment and tumor 
assessments should be continued until the new lesion has been confirmed. If repeat scans confirm there is a new lesion, then the progression date should be declared using the date of the initial scan.  
10.11.3.  Disease Response Status at Each Imaging Assessment  
The timepoint assessment will include deriving the Target Lesion Response, Non Target 
Lesion  Response and the Overall Response based on the lesion status of the target, non- target 
and/or new lesions assessed at the post -baseline imaging visit.  
For target lesion response of Complete Response/Partial Response, imaging must be 
evaluable, with all anatomy covered, and with no target lesion with status of Not 
Evaluable/Not Assessed.  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 103 
 [IP_ADDRESS].  Target Disease Response Status  
Target lesion response definitions for each imaging assessment:  
Complete Response (CR)  Complete disappearance of all target lesions with the exception of 
nodal disease. All target lymph nodes must decrease to normal size 
(short axis  <10 mm).  
Partial Response (PR)  At least a 30% decrease in the sum of the diameters  of TL, taking as 
reference the baseline sum of diameters  
Stable (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD  
Progressive Disease (PD)  At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on study).  
In addition to the relative increase of 20%, the s um must also 
demonstrate an absolute increase of at least 5mm.  
Not Evaluable (NE)  If the SOD does not derive PD, and:  
• One or more of the target lesions have not been assessed; OR  
• One or more target lesion cannot be measured accurately due to poor 
technica l quality; OR  
• One or more target lesions were excised or irradiated and have not reappeared or increased; OR  
• Imaging modality or assessment method is inconsistent with baseline assessment  
[IP_ADDRESS].  Nontarget Disease Response Status  
NTL response definitions for each imaging assessment:  
Complete Response (CR)  Disappearance of all NTL since baseline. All lymph nodes must be 
non-pathological in size (<10 mm short axis).  
Non-Complete 
Response/Non-Progressive 
Disease  Persistence of one o r more non target lesions  
Progressive Disease (PD)  Unequivocal progression of existing NTL. Unequivocal progression 
may be due to progression in one lesion only or in several lesions. 
Generally, the overall tumor burden must increase sufficiently to 
merit discontinuation of therapy.  
Not Evaluable (NE)  An overall non -target assessment cannot be made at this visit based 
on one or more of the following:  
• One or more of the NTL have not been assessed; OR  
• One or more NTL cannot be assessed due to poor technical quality; OR 
• One or more NTL were excised or irradiated and have not reappeared or increased; OR  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 104 
 • Imaging modality or assessment method is inconsistent with baseline 
assessment and impacts the ability to accurately assess the disease 
status 
[IP_ADDRESS].  New Lesions  
The appearance of any new unequivocal malignant lesion indicates disease progression. If a 
new lesion is equivocal, for example due to its small size, continued assessment will clarify 
the etiology. If repeat assessments confirm the lesio n, then progression should be recorded on 
the date of the initial assessment. A lesion identified in an area not previously scanned will 
be considered a new lesion.  
New lesion definition for each imaging assessment:  
Yes Definitely present  
No Not present, or uncertain  
[IP_ADDRESS].  Overall Response at Each Imaging Assessment  
Table [ADDRESS_421802] 1.1 Overall Response at Each Assessment  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR NA No CR 
NA CR No CR 
CR Non-CR/Non -PD No PR 
CR NE No PR 
PR Non-PD, NE  No PR 
SD Non-PD, NE  No SD 
NE Non-PD, NE  No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
NA Non-CR/Non -PD No Non-CR/Non -PD 
NA NA No NED  
NA NE No NE 
CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease; NE=not evaluable/not all 
assessed/missing; NED=no evidence of disease (relevant when no TL and NTL at baseline); NA= Not Applicable 
(relevant when no TL and/or NTL at baseline); NTL=non -target lesion; TL=target lesion  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421803] 1.1 Overall Response at Each Assessment  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/Non -PD No Non-CR/Non -PD 
NE No NE 
Unequivocal Progressive Disease  Yes or No  PD 
Any Yes PD 
CR=complete response; PD=progressive disease; NE=Not Evaluable/Not Assessed  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 106 
 10.12.  Appendix 12: Abbreviations  
The following is a list of abbreviations used in the protocol.  
Abbreviation  Term  
AE adverse event  
AI aromatase inhibitor  
AIDS  acquired immunodeficiency syndrome  
AJCC  American Joint Committee on Cancer  
ALT  alanine aminotransferase  
Alk Phos  alkaline phosphatase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
ASCO  American Society of Clinical Oncology  
AST  aspartate aminotransferase  
AUC  area under the curve  
AV atrioventricular  
BCRP  breast cancer resistance protein  
BCS  breast conserving surgery  
BP blood pressure  
bpm beats per minute  
BUN  blood urea nitrogen  
C Cycle  
C1D1  Cycle [ADDRESS_421804] computerized tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
Ctrough trough concentration  
CYP  cytochrome P450  
D Day 
DC 50 half-maximal degradation concentration  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421805]  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDB  exposure during breastfeeding  
EDP  exposure during pregnancy  
ER estrogen receptor  
ER+ estrogen receptor positive  
EU European Union  
EudraCT  European Clinical Trials Database  
FDA  Food and Drug Administration ([LOCATION_002])  
FIH first-in-human  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
GI gastrointestinal  
GI50 half-maximal growth inhibition  
GLM generalized linear model  
GLP  good laboratory practices  
GSPT1  G1 to S Phase Transition 1 gene  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HER2  human epi[INVESTIGATOR_3506] 2  
HIV human immunodeficiency virus  
HR+  hormone receptor positive  
IB investigator’s brochure  
IC50 half-maximal inhibitory concentration  
ICD informed consent document  
ICH International Council for Harmonisation  
ID identification  
IHC immunohistochemist ry 
IND investigational new drug  
INR international normalized ratio  
IP investigational product  
IRB institutional review board  
IRT interactive response technology  
LFT liver function test  
LSM least square means  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421806]  modified  Response Evaluation Criterion in Solid Tumors  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
NA not applicable  
NCI National Cancer Institute  
NE not evaluable/not all assessed/missing  
NED  no evidence of disease (relevant when no TL and NTL at baseline)  
NET  neoadjuvant endocrine therapy  
NOAEL  no-observed -adverse -effect level  
NOD/SCID  nonobese diabetic/severe combined immunodeficiency  
NTL  non-target lesion  
nsAI  nonsteroidal aromatase inhibitor  
ORR  objective response rate  
pCR pathologic complete response  
PD pharmacodynamics(s)  
P-gp p-glycoprotein  
PgR progesterone receptor  
PK pharmacokinetic(s)  
PO oral(ly) 
POC  proof of concept  
PPI [INVESTIGATOR_340723] T argeting Chimera  
PS performance status  
PT prothrombin time  
PTT partial thromboplastin time  
PVC  premature ventricular contraction/complex  
QD every day  
QTc corrected QT  
QTcF  corrected QT (Fridericia method)  
RECIST  Response Evaluation Criteria in Solid Tumors  
RNA  ribonucleic acid  
RP2D  recommended phase [ADDRESS_421807] characteristics  
SoA schedule of activities  
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421808]  of care  
SOD  sum of the diameters  
SRC  safety review committee  
SRSD  single reference safety document  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t1/[ADDRESS_421809]  upper limit of normal  
US [LOCATION_002]  
USPI  [INVESTIGATOR_340724]-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 110 
 10.13.  Appendix 1 3: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the TOC. The protocol amendment summary of changes tables for past amendments  can be found below:  
 Amendment to Original Protocol  (14 D ec 2022) 
Overa ll Rationale for the Amendment: Updates made  
 
Section # 
and Name  [CONTACT_340771] 
12.1:  
Requirements  Addition of Appendix 12.1: 
 Requirements  
• Addition of suggestion for 
bone mineral density testing due to anastrozole lowering circulating estrogen levels  
• Details added regarding co -
administration of PPIs and H2 blockers. The concomitant use of PPIs with ARV-471 is not 
recommended. H2 blockers (eg, cimetidine, famotidine) or local antacids (eg, aluminum hydroxide, calcium carbonate, bismuth subsalicylate) may be used.  
Clarification that only participants for whom neoadjuvant endocrine monotherapy is deemed appropr iate are eligible  
• Exclusion criteria now to exclude patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose 
malabsorption.  
 Nonsubstantial  
 

ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 112 
 10.14.2.  Investigator Acknowledgment  
PROTOCOL TITLE:  An Open -Label, Randomized, Non-Comparative Phase [ADDRESS_421810] -Menopausal Women with ER+ /HER2 – Breast Cancer in 
the Neoadjuvant Setting  
PROTOCOL NO:  ARV -471- BC-201 
VERSION:  Global Amendment #[ADDRESS_421811] their origin in the Declaration 
of Helsinki and that are consistent with Good Clinical Practices and the applicable laws and 
regulations. Acceptance of this document constitutes my agreement that no unpublished information contained herein will be published or disclosed without prior written approval 
from th e Sponsor.  
Instructions to the Investigator: Please SIGN and DATE this signature [CONTACT_3264]. PRINT your 
name, title, and the name [CONTACT_340772]. Return the signed copy to Arvinas Estrogen Receptor, Inc.  
 
I have read thi s protocol in its entirety and agree to conduct the study accordingly:  
 Signature [CONTACT_7919]:  Date:   
Printed Name:   
[CONTACT_202094]:   
 Name/Address of Center:  
 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421812] cancer: American Society of Clinical Oncology / College of American Pathologists  
guideline update. Arch Pathol Lab Med. 2020 May;144(5):545-63. 
ARIMIDEX® (anastrozole) [ADDRESS_421813] 
Characteristics. Cheshire, [LOCATION_006]: [COMPANY_008] [LOCATION_006] Ltd. Revised 2011. Available at: 
https://www.ema.europa.eu/en/documents/referral/arimidex -article -30-referral -annex -
iii_en.pdf.  ARIMIDEX® (anastrozole) tablet for oral use: United  States Prescribing Information. 
Wilmington, DE: [COMPANY_008] Pharmaceuticals LP; Revised: Oct 2010. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020541s026lbl.pdf. 
ARV -471 Investigator's Brochure, v4.[ADDRESS_421814] cancer: 
current  knowledge and future perspectives. Int J Mol Sci. 2020;21(10):3528.  
Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as  
preoperative therapy in postmenopausal women with hormone receptor -positive breast 
cancer: the Pre- Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 
2006 May 15;106(10):2095-103.  Denduluri N, Miller K, O’Regan RM. Using a neoadjuvant approach for evaluating novel 
therapi[INVESTIGATOR_340725]. American Society of Clinical Oncology Educational 
Book. 2018 May 23;38:47-55. 
Donovan KA, An J, Nowak RP, et al. Thalidomide promotes degradation of SALL4, a 
transcription factor implica ted in Duane Radial Ray syndrome. eLife. 2018;7:e38430.  
Dowsett M, Smith IE, Ebbs SR, et al. IMPACT Trialists. Short- term changes in Ki -[ADDRESS_421815] cancer with anastrozole or tamoxifen alone or 
combined correlate with recurrence- free survival. Clin Cancer Res. 2005 Jan 15;11(2 Pt 
2):951s- 8s. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck 
S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij 
J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009 Jan;45(2):228-47. 
Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial [published correction 
appears in Breast Cancer Res Treat. 2008 Nov;112(2):371]. Breast Cancer Res Treat. 
2007;[ADDRESS_421816] 1(Suppl 1):33-43.  
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between 
letrozole, anastrozole, and exemestane for postmenopausal women with estrogen 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #[ADDRESS_421817] cancer: clinical and biomarker outcomes and predictive value 
of the baseline PAM50 -based intrinsic subtype —ACOSOG Z1031. Journal of Clinical 
Oncology. 2011 Jun 10;29(17):2342.  
FDA. Drug Approval Package. Faslodex (Fulvestrant) Injection; Company: [COMPANY_008] 
Pharmaceuticals . (Application No.: 21- 344; Approval Date: 4/25/2002). Rockville (MD): 
U.S. Food and Drug Administration (U.S. FDA), Center for Drug Evaluation and Research 
(CDER); 2002. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-344_FulvestrantFaslodex.cfm. 
FDA. Guidance for Industry. In vitro drug interaction studies – cytochrome P450 enzyme - 
and transporter -mediated drug interactions. January 2020. https://www.fda.gov/regulatory-
information /search -fda-guidance-documents/vitro-drug- interaction -studies-cytochrome-
p450- enzyme -and-transporter- mediated -drug- interactions . 
Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopaus al 
women with early breast cancer: NCIC CTG MA.27 -a randomized controlled phase III trial. 
J Clin Oncol . 2013 Apr 10;31(11):1398-404. 
Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, 
Version 4.2021: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2021 May 1;19(5):484-93. 
Guerrero -Zotano AL, Arteaga CL. Neoadjuvant trials in ER+ breast cancer: a tool for 
acceleration  of drug development and discovery. Cancer Discovery. 2017 Jun;7(6):561-74. 
Hamilton E, Vahdat L, Han HS, et al. First- in-human safety and activity of ARV -471, a 
novel PROTAC  estrogen receptor degrader, in ER+/HER2 - locally advanced or metastatic 
breast cancer . Cancer Res. 2022;82(4_suppl).  
Howell A, Cuzick J, Baum M , et al; ATAC Trialists' Group. Results of the ATAC 
(Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1 -7;365(9453):60-2. 
Hurvitz SA, Martin M, Press MF, et al. Potent Cell -Cycle Inhibition and Upregulation of 
Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II 
Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 Feb 1;26(3):566-
580. doi: 10.1158/ 1078-0432.CCR-19-1425. 
Hurvitz SA, Quiroga V, Park YH, et al.  Neoadjuvant giredestrant (GDC -9545) + palbociclib 
versus anastrozole + palbociclib in postmenopausal women with estrogen receptor -positive, 
HER2 -negative, untreated early breast cancer: Primary analysis of the randomized, open-
label, phase II coopERA breast cancer study. San Antonio Breast Cancer Symposium 2021. 
Cancer Res 15 February 2022a ; 82 (4_Supplement): PD13–06.  
Hurvitz SA, Schott AF (Presenter), Ma C, et al. ARV -471, a PROTAC® ER degrader  in 
advanced ER -positive/human epi[INVESTIGATOR_3506] 2 (HER2) -negative breast 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 115 
 cancer: phase 2 expansion (VERITAC) of a phase 1/[ADDRESS_421818]  Cancer 
Symposium 2022. 08 Decem ber 2022b; Presentation GS3-03. 
Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy 
for the Adjuvant Treatment of HR+, HER2- , Node -Positive, High -Risk, Early Breast Cancer 
(monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-3998. 
Juric  D, Ciruelos EM, Rubovszky G , et al. Alpelisib (ALP)+ fulvestrant (FUL) for advanced 
breast cancer (ABC): Phase [ADDRESS_421819] Cancer 
Symposium (SABCS) (Abstract # GS3- 08) on December 2018 Dec 4 (Vol. 6).  
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, 
and targeted therapy for breast cancer: ASCO guideline. Journal of clinical oncology: official 
journal of the American Society of Clinical Oncology. 2021 May 1;39(13):1485-505. 
Kuter I, Gee JM, Hegg R, Singer CF,  et al. Dose- dependent change in biomarkers during 
neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase 
II study. Breast Cancer Research and Treatment. 2012 May;133(1):237-46. 
Lerebours F, Rivera S, Mouret ‐Reynier MA, et al. Randomized phase 2 neoadjuvant trial 
evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor –
positive, human epi[INVESTIGATOR_3506] 2–negative breast cancer patients: Results 
of the UNICANCER CARMINA 02 French tr ial (UCBG 0609). Cancer. [ADDRESS_421820];122(19):3032-40. 
Li Y, Yang D, Yin X, et. al. Clinicopathological Characteristics and Breast Cancer –Specific 
Survival of Patients  With Single Hormone Receptor –Positive Breast Cancer. JAMA Netw 
Open. 2020;3(1):e1918160.  
Lindeman GJ, Bowen R, Jerzak KJ, et al. Results from VERONICA: A randomized, phase II 
study of second- /third -line venetoclax (VEN)+ fulvestrant (F) versus F alone in estrogen 
receptor (ER) -positive, HER2- negative, locally advanced, or metastatic breast cancer  
(LA/MBC). American  Society of Clinical Oncology Annual Meeting 2021.  
Ma CX, Suman VJ, Leitch AM, et al. ALTERNATE: Neoadjuvant endocrine treatment 
(NET) approaches  for clinical stage II or III estrogen receptor -positive HER2- negative breast 
cancer (ER+ H ER2– BC) in postmenopausal (PM) women: Alliance A011106 2020.  
Martí C, Sánchez- Méndez JI. The present and future of neoadjuvant endocrine therapy for 
breast cancer treatment . Cancers (Basel). 2021;13(11):2538.  
Quenel -Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a 
randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone -receptor -positive breast cancer. 
British Journal of Cancer. 2015 Aug;113(4):585- 94. 
ARV-471 (PF -07850327)  
Study ARV -471-BC -201 Global Amendment #1 
 
CONFIDENTIAL  
Page 116 
 Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short -term biological 
effects of 7alpha- [9-(4,4,5,5,5 -pentafluoropentylsulfinyl)-nonyl]estra- 1,3,5, (10) -triene -
3,17beta- diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast 
cancer. Cancer Res. 2001;61(18):6739-6746. 
Robertson JF, Dixon JM, Sibbering DM, et al. A randomized trial to assess the biological 
activity of short -term (pre-surgical) fulvestrant [ADDRESS_421821] Cancer Res earch. 2013 
Apr;15(2):1-0. 
Robertson JF, Evans A, Henschen S, et al. A randomized, window of opportunity study 
comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with 
ER+ HER2 -primary breast cancer. Clin Cancer Res. 2020 Aug 15;26(16):4242-[ADDRESS_421822] 
cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative 
Anastrozole, Tamoxifen , or Combined with Tamoxifen (IMPACT) multicenter double -blind 
randomized trial. J Clin Oncol. 2005 Aug 1;23(22):5108-16. 
Smith I, Yardley D, Burris H, et al. Comparative Efficacy and Safety of Adjuvant Letrozole 
Versus Anastrozole in Postmenopausal Patients With Hormone Receptor -Positive, Node -
Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus 
Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol. 2017 Apr 1;35(10):1041-1048. 
Smith IE, Robertson J, Kilburn L, et al. Long- term outcome and prognostic value of K i67 
after perioperative endocrine therapy in postmenopausal women with hormone -sensitive 
early breast cancer (POETIC): an open -label, multicentre, parallel -group, randomised, phase 
3 trial. Lancet Oncol 2020; 21: 1443–54.  
Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen 
receptor –positive breast cancer: a systematic review and meta- analysis. JAMA Oncology. 
2016 Nov 1;2(11):1477-86. 
Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of 
Incide nce and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 
2021;71:209–249. 
Tatetsu H, Kong NR, Chong G, et al. SALL4, the missing link between stem cells, 
development and cancer. Gene. 2016;584:111-119. 
The Breast International Group (B IG) [ADDRESS_421823] Cancer. N Engl J Med 2005; 
353:2747-2757. 
Wang Y, He L, Song Y, et al. The tumour response of postmenopausal hormone receptor -
positive breast cancers  undergoing different types of neoadjuvant therapy: a meta -analysis. 
BMC Women's Health. 2020 Dec;20(1):1-1. 